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ABSTRACT
Misfolded protein aggregates are one of the significant contributing factors in
many neurogenerative diseases including Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, and others. My PhD research project was to study various aspects
of amyloid-β peptide, a 40-42-residue peptide and the primary component of the senile
plaques found in Alzheimer’s disease (AD) brains.
One objective of my research was to purify and characterize the intermediate
Aβ42 species using an array of biophysical techniques like size exclusion
chromatography, fluorescence assays, circular dichroism, cellular assays, and protein
assays.
The other major research thrust of my project was to study the role of microglial
cell derived extracellular vesicles in the aggregation of Aβ42. Isolation of extracellular
vesicles with Aβ42 protofibrils from the primary microglial cells or BV-2 microglial cells
and their characterization with dynamic light scattering, NBD fluorescence, flow
cytometry, and microscopy techniques enabled to explore the effect of these vesicles in
Aβ aggregation.
Neuroinflammation is another important aspect of AD pathology. So, I was
involved in the screening of several Lipid A based organic compounds to study their
potential to antagonize the release of inflammatory cytokine, TNF-α, induced by TLR4
ligands. We have identified and established the structure-activity relationship of the
effective antagonists.
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CHAPTER 1- INTRODUCTION
1.1. Overview of Alzheimer’s disease (AD)
Alzheimer’s disease (AD) is a disorder that causes the degeneration of brain cells
and characterized by declination in thinking and independence in personal daily activities
(Breijyeh and Karaman 2020). It is the most common cause of dementia among the
elderly population. AD comprises about 70% of the total dementia cases and is the 6th
leading cause of death. According to the updated calculation in 2021 report of
Alzheimer’s association an estimated 6.2 million Americans over the age of 65 years are
living with Alzheimer’s (Association 2021). The prevalence of the disease increases with
age. Some people might develop the disease at comparatively younger age. But the
population with early onset of AD is relatively low. Alzheimer’s disease is thought to
begin 20 years or more before the appearance of actual symptoms (Braak, Thal et al.
2011).
AD continuum comprises three broad phases: preclinical AD, mild cognitive
impairment (MCI) due to AD and dementia due to AD. Based on the effect of symptoms
on one’s ability to carry out daily activities, dementia due to AD can be further broken
down into mild, moderate and severe stages (Jack, Albert et al. 2011). The time spent by
individuals in each stage varies depending on the age, genetics, biological sex and other
factors (Vermunt, Sikkes et al. 2019).
During preclinical AD, there is measurable changes in the brain of the individuals
indicating some signs of AD biomarkers like abnormal level of the beta amyloid and
decreased metabolism of the glucose. However, the brain can compensate the effect these
1

biomarkers in this phase. So, the individuals do not have any symptoms and they can
carry out their functions normally (Sperling, Aisen et al. 2011). People with MCI due to
Alzheimer’s have some problems with memory and thinking, in addition to the existence
of regular AD biomarkers. MCI is the key area of interest for researchers for drug
discovery as the disease progression can be halted at this stage and symptoms are
noticeable to family members (Albert, DeKosky et al. 2011). Alzheimer’s dementia is
characterized by all the common symptoms of Alzheimer’s like noticeable memory loss,
impairment in thinking and reasoning abilities in combination with biomarker evidence
of Alzheimer’s related brain change (McKhann, Knopman et al. 2011).
The risk factors for disease are but not limited to age and gender, genetic factors,
infections, environmental factors, head injuries, cardiovascular diseases, lifestyle,
obesity, diabetes etc. (Richard 2019). Out of several hypotheses for the cause of AD, the
highly accepted ones are cholinergic and the amyloid hypothesis. Cholinergic hypothesis
emphasizes the impairment in cholinergic function as the risk factor for AD while
amyloid hypothesis focuses on the alteration in amyloid β- protein production and
processing (Anand and Singh 2013).
Despite the immense research effort to overcome the social and economic
problems from AD, little or nothing has been achieved so far. Failure of clinical trials of
drugs proposed to ameliorate the effect of disease is very common news in the field. The
complex pathology and lack of biomarkers for early detection of disease are posing great
challenges to develop any effective therapeutic strategies. However, researchers have
accepted all the challenges and continued to find alternative ways to contend the disease.
As a result, there are more than 92 pharmacologically potent compounds are under the
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study to explore their possible ability for the modification of disease. A deadline of 2025
was set by global leaders in 2014 at G8 summit to find an effective disease modifying
therapy, although this aim was not set based on any scientific background (Breijyeh and
Karaman 2020).

A.

B.

Figure 1.1. AD facts and Figures. Alzheimer’s disease prevails among the elderly
people and number of individuals with AD is increasing every year. A) Age distribution
of AD related patients. B) Number of patients 65 years of age and older with AD in last
five years. Source: https://www.alz.org/.
1.2. AD pathology
Alois Alzheimer noticed the deposition of amyloid plaques and significant loss of
neurons in one of his patients with progressive cognitive deterioration. He published his
findings in 1907 and described the condition as serious problem of the cerebral cortex.
This medical condition was named as Alzheimer’s disease by Emil Kraepelin. Since then,
Alzheimer’s disease is always in the center of discussion in the scientific world of
neuroscience and dementia (Castellani, Peclovits et al. 2014). AD brain is mainly
characterized by two neuropathological changes: (Selkoe 1991) 1) positive lesions due to
the accumulation of neurofibrillary tangles (NFTs), amyloid plaques, dystrophic neurites,
neuropil threads and other brain deposits. 2) Negative lesions due to the loss of neurons,
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neuropils, and synapses. In addition to this, neuroinflammation, oxidative stress, and
injury of cholinergic neurons also contribute to the neurodegeneration (Khan, Ikram et al.
2021). However, presence of extracellular senile plaques and intracellular neurofibrillary
tangles are considered as major pathological hallmarks of Alzheimer’s disease (Sengoku
2020). Senile plaque is composed of central core of amyloid beta (Aβ) protein surrounded
by dystrophic neurites and reactive glial cells (Hardy and Higgins 1992) whereas the
NFTs are made of aggregates of hyperphosphorylated tau protein (Perl 2010).
Genetically, mutation in amyloid precursor protein (APP) or enzymes involved in
Aβ generation initiate the disease and tangles are more closely related to neuronal loss
and clinical symptoms. So, the current linear model of disease for the neural system
failure, neurodegeneration and cognitive decline hypothesizes the spreading of misfolded
tau protein assemblies through the cortex following the pathophysiological cascade
initiated by Aβ plaque or soluble Aβ species (Busche and Hyman 2020). Inhibition of Aβ
generation by using β–or γ–secretase inhibitors prevent the tau pathology (Lee,
Velazquez Sanchez et al. 2016) which suggests that tau pathology is downstream of Aβ.
There are growing evidence of synergic effect of Aβ and tau in the pathogenesis of AD
which is mediated by microglia (Busche and Hyman 2020).

4

1.3. Amyloid Protein
The term amyloid refers to the extracellular deposits of insoluble fibrous
proteinaceous structures formed from soluble proteins. These degradation resistant
structures are involved in the pathogenesis of several diseases known as amyloidosis
(Rambaran and Serpell 2008). Structurally, β-sheets are main constituents of amyloids

A

B

Figure 1.2. AD pathology. Pathological hallmarks of Alzheimer’s disease.
A) Classical neural lesions of AD as demonstrated by Bielschowsky silver
stain (Selkoe 1991). A central core of senile plaques mainly composed of
amyloid is surrounded by structurally abnormal neurites (open arrowhead).
There are darkly stained neurofibrillary tangles occupying much of the
cytoplasm of diseased neuron in contrast to the golden brown (arrow) of
adjacent normal neuron. B) Senile plaques (middle) create a hostile
cellular environment with hyperactive neurons, activated microglia and
spine loss in comparison to healthy brain (left). Presence of both Aβ and
tau (right) suppresses neuronal activity, enhances microglial activation and
spine loss.(Busche and Hyman 2020).
with their characteristic cross-β conformation. The fibrillar structure of the amyloids as
indicated by the Congo red staining (Divry and Florkin 1927) and its apple-green
birefringence under polarized light has been confirmed by transmission electron
microscope (Cohen and Calkins 1959) and x-ray diffraction patterns (Eanes and Glenner
1968). Despite the difference in amino acid sequence of different types of amyloids the
common β-sheet polypeptide backbone makes them fibrillar, insoluble and resistant to
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proteolysis (Sunde, Serpell et al. 1997). The aggregation of soluble monomeric protein
into amyloid fibrils is triggered by the induction of conformational changes leading to the
erroneous protein folding or misfolding (Eakin, Berman et al. 2006).
The insoluble and heterogenous nature of amyloid fibrils are the major hurdles to
using the common techniques for their structure determination. However, implementation
of some advanced techniques like X-ray fiber diffraction, atomic force microscopy
(AFM), transmission electron microscopy (TEM), solid state nuclear magnetic resonance
(ssNMR), cryo-EM or electromagnetic resonance have revealed the many structural
aspects of amyloid fibrils (Bruggink, Müller et al. 2012). As for example, long, straight,
and unbranched nature of amyloid fibrils have been established from AFM and TEM
study. Furthermore, these are made up of varying number of discrete protofilament units
twisting around one another. These protofilaments are composed of cross β-sheet
structures and arranged perpendicular to fiber axis. So, the general models of amyloid
fibrils are cross-β in nature and β-sheet conformation forms the core of the structure.
Interaction among the side chains of peptide residues provides the stability to the
structure (Rambaran and Serpell 2008).
Owing to the pathological role of amyloids in several disease pathogenesis,
attempts were made to modulate the amyloid formation or inhibit the enzymes involved
in the process. But the cellular toxicity of most of the synthetic small molecules keep
them from being used as potential drugs. So, the therapeutic strategy is more focused on
development of biological ligands like monoclonal antibodies raised against amyloid
which is more successful at reduction in toxic soluble intermediates or clearance of
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plaques. Still, even this immunological approach has not resulted in any conclusive
therapeutic agents against the disease
1.3.1. Amyloid β-Generation and aggregation
Amyloid β is one of the various forms of amyloid proteins implicated in the
pathogenesis of Alzheimer’s disease. It is a peptide of 39-42 amino acids generated by
the specific proteolytic cleavage of a transmembrane protein, amyloid precursor protein
(APP) in vivo (Chen, Xu et al. 2017). Self-assembly of peptide via non-covalent
nucleation-dependent polymerization results in varieties of aggregated structures with
significant β-sheet secondary structure (Walsh, Hartley et al. 1999, Kirkitadze, Condron
et al. 2001). The most widely accepted amyloid cascade hypothesis of AD emphasizes
the precipitation of Aβ monomers into amyloid form as the primary step in the disease
pathology (Finder and Glockshuber 2007). Formation of Aβ fibrils is followed by
neurofibrillary tangles and cellular death (Hardy and Higgins 1992, Ittner, Chua et al.
2016). A plethora of studies indicate the higher toxicity of soluble intermediate species
rather than the individual monomers or final plaques (Haass and Selkoe 2007).
Neurotoxic effect of Aβ species is due to their ability to cause oxidative stress, form ion
channels and disrupt cell membranes and activate the cellular processes like apoptosis
and inflammation (Carrillo-Mora, Luna et al. 2014).
Generation of Aβ from APP is accompanied by two proteases: β-secretase and γsecretase. APP proteolysis is initiated with the cleavage of N-terminus by amyloidogenic
β-secretase or non-amyloidogenic α-secretase to release APPsβ or APPsα (N-terminal
fragments) and C99 or C83 (membrane bound C-terminal fragments) respectively (Figure
1.3). Both C-terminal fragments can be further cleaved by one or more γ-secretases to
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release and secrete pathogenic Aβ (from C99) or non-pathogenic p3 peptide (from C83)
(Southam, Stennard et al. 2019, Lichtenthaler, Tschirner et al. 2022). γ-Secretases can
cleave C99 at different sites resulting in two major isoforms of Aβ, Aβ40 and Aβ42.
Presence of two extra hydrophobic residues, isoleucine and alanine, renders the later
isoform more prone to the aggregation. So, increased Aβ42/ Aβ40 marks the early onset
of AD (Gu and Guo 2013).
Aβ aggregation proceeds through thermodynamically unfavorable higher to lower
entropic state (Hellstrand, Boland et al. 2010). However, the hydrophobic interaction
among the amino acid residues stabilizes the aggregated forms (Chaturvedi, Siddiqi et al.
2016). The conformational change during aggregation from random coil or α-helix into βsheet facilitates the ease for stronger hydrophobic interactions. Aβ aggregation kinetics
follows the nucleation dependent polymerization with lag phase, elongation phase and
equilibrium or stable phase. (Figure 1.4) (Matuszyk, Garwood et al. 2022). The rate
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Figure 1.3. APP proteolysis. Amyloidogenic and non-amyloidogenic proteolysis of
amyloid precursor protein (APP). Amyloidogenic processing of APP starts with the
proteolytic cleavage by an aspartic protease, β-secretase (BACE1) followed by γsecretase generating Aβ. In non-amyloidogenic processing of APP, α-secretase
(mediated by ADAM10 and related proteases) cleavage prevents the generation of Aβ.
γ-secretase cleaves C-terminal fragments at different sites resulting in the heterogenous
mixture of mainly Aβ40 and Aβ42. The ratio of Aβ40 and Aβ42 decreases under
pathogenic condition (Lichtenthaler, Tschirner et al. 2022).
determining steps in Aβ aggregation is the association of monomers into nucleation
seeds. This kinetically unfavorable process of polymerization includes primary and
secondary nucleation. The slowest process of Aβ elongation in primary nucleation step
results in the long lag phase. Association of monomers into oligomers or fibrils depends
on the peptide environment as it is responsible for the stability of peptide. The formation
of seed accelerates the addition of further monomers and results in the relatively faster
elongation phase. Once there is critical mass of aggregates it catalyzes the secondary
nucleation process when new nuclei are formed in the surface of aggregates. As the
number of fibrils increases secondary nucleation overrides primary nucleation forming
more toxic intermediate species (Cohen, Linse et al. 2013). Aggregation process
continues until all the available monomers get converted into fibrils. The end of
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aggregation process is marked by presence fibril growth plateau is reached in kinetic
curve.

Figure 1.4. Aβaggregation. Nucleation, aggregation, and relationship of
different Aβ aggregation species. Aggregation of Aβ begins with much slower
lag phase during which monomers self-aggregate to produce nucleation seeds.
Formation of enough number of seeds accelerates the formation of aggregated
species in growth phase which eventually leads to the formation fibrils. The
aggregation process continues until all the monomers are depleted in an
equilibrium phase forming a plateau. (Matuszyk, Garwood et al. 2022).
1.3.2. Structural conformations of Aβ
Intrinsic nature of Aβ monomers is as unstructured peptides which are highly
unstable. However, development of techniques like solid state NMR or cryo-EM have
enabled the study of molecular structure of Aβ peptides. Solid-state NMR (Tycko 2015)
(Chen, Xu et al. 2017) (Colvin, Silvers et al. 2016), and more recently cryo-electron
microscopy (Gremer, Schölzel et al. 2017) (Kollmer, Close et al. 2019), studies of Aβ40
and Aβ42 fibrils indicate an underlying structure of two intertwined protofilaments with
hydrogen-bonding running parallel to fibril axis, a well-ordered hydrophobic core, and a
disordered N-terminal region that is not part of the cross-β-sheet structure (Crescenzi,
Tomaselli et al. 2002). Simulation based on NMR studies (Sgourakis, Yan et al. 2007)
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shows reduced flexibility in the C-terminus of Aβ42 compared to Aβ40, which is
responsible for the higher amyloid forming propensity of Aβ42. Furthermore,
hydrophobic C-terminal of Aβ plays key role for the transformation from α-helical to βsheet structure and determining aggregation state in AD (Mirza, G Pillai et al. 2014).
The nucleation dependent aggregation of Aβ monomers into insoluble fibril via
noncovalent self-assembly proceeds with a polydisperse mixture of soluble oligomers,
and/or protofibrils with varied extent of β-sheet content (Nichols, Colvin et al. 2015).
Assemblies of monomers can range from low-molecular weight oligomers to high
molecular weight protofibrils and fibrils. Oligomers are more transient than fibrils and
isolation of stable and homogenous population of oligomers is not easy. So,
characterization of oligomers is much complicated, and less information is available
about their structure (Gremer, Schölzel et al. 2017). Aβ oligomers are mainly extended
coil or β-sheet structures as suggested by circular dichroism (CD) and infrared
spectroscopy measurement (Kayed, Head et al. 2003). 40% of the total backbone
hydrogen bonds resistant to hydrogen-deuterium exchange in oligomers in contrast of
50% in mature amyloid fibrils (Kheterpal, Wetzel et al. 2003), (Kheterpal, Zhou et al.
2000). The relationship between oligomers and fibrils is not understood completely, but
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they share some similar structural elements as evidenced by several publications
(Gremer, Schölzel et al. 2017).
1.4. Amyloid β and AD
The pathogenesis of Alzheimer’s diseases kicks off with the accumulation of

Figure 1.5. Different structural representations of Aβ species including
monomer, oligomer, S-shaped Aβ, U-shaped Aβ, and Aβ-protofibrils
(Grasso and Danani 2020).
amyloid-β protein in the hippocampal region of brain. The precise mechanism of the
synaptic loss and cognitive impairment due to Aβ accumulation is not fully explored and
still under intense investigation (Hampel, Hardy et al. 2021). However, there is a
consensus that small soluble oligomeric Aβ species (oAβ) are actual pathogenic species
of the aggregation pathway. OAβs are capable of enhancing long-term depression (LTD)
and impairing long-term potentiation in hippocampus (O'Nuallain, Freir et al. 2010).
They can directly disrupt neuronal NMDA receptors, AMPA receptors, and metabotropic
glutamate receptors (mGluRs) (Bloom 2014).
Measurement of average rate of Aβ production and clearance in cerebrospinal
fluid (CSF) of cognitively healthy individuals estimated by stable isotope labeling
12

kinetics shows the rate of clearance is about 8% of the rate of production. Slight
imbalance of production-clearance process, especially, reduction in clearance, is
sufficient to cause Aβ accumulation. Normal Aβ turnover is balanced by bulk-flow of
CSF via blood brain barrier (BBB) the perivascular circulation and the glia-lymphatic
system (Bateman, Munsell et al. 2006). The molecular events of Aβ toxicity mechanism
can be interpretated by amyloid degradation toxicity hypothesis. Aβ peptide is degraded
by lysosomal peptidases as it enters the cell by endocytosis and the resulting fragments
form amyloid channels permeabilizing the lysosomes. The neutralization of lysosomal
content inactivates degradation enzymes which results in the accumulation of undigested
amyloid (Zaretsky and Zaretskaia 2021).
1.5. Innate immunity
Innate immune system is the first line defense mechanism against invading
pathogens developed in living organisms comprised of physical and chemical barriers as
well as immune responses by immune cells (Medzhitov and Janeway Jr 2000). Protection
provided by epidermis, ciliated respiratory epithelium, vascular endothelium, and
mucosal surfaces against microbes represents the physical and chemical defense
mechanism. Likewise cellular component of innate immune system is assisted by
phagocytic cells and antigen presenting cells (APCs) like macrophages, granulocytes and
dendritic cells which are relatively non-specific (Iwasaki and Medzhitov 2004). These
cells express a limited number of germ line encoded pattern recognition receptors (PRRs)
and recognition of evolutionary conserved structures on pathogens by these receptors is
the basis for cell mediated innate immune system (Akira, Uematsu et al. 2006)
(Medzhitov and Janeway Jr 2000). The main classes of PRRs are Toll-like receptors
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(TLRs), nucleotide oligomerization and binding domain (NOD)-like receptors (NLR), Ctype lectin receptors (CLRs), RIG-I (retinoic acid inducible gene-I)-like receptors
(RLRs), and IFI200 family member absent in melanoma 2 (AIM2) (Martinon, Mayor et
al. 2009) (Lamkanfi and Dixit 2012) (Lamkanfi and Dixit 2011) (Abderrazak, Syrovets et
al. 2015) (Venegas and Heneka 2017). These receptors have made the innate immune
system quite sophisticated system for sensing “danger” whilst remaining unresponsive to
the molecules and particles regarded as posing no threat to the general well-being of cells
(Schroder and Tschopp 2010) PRRs recognize pathogen-specific molecules, aberrant
localization of foreign or self-molecules, or abnormal molecular complexes during
microbial infection. This event triggers PRR mediated signaling and activates innate
immune system. Activation of innate immunity ultimately resolves the infection or causes
inflammatory diseases or autoimmunity (Mogensen 2009). Unlike adaptive immunity,
which is developed in response to the infection, innate immunity is already present in the
body
1.5.1. Immune cells
There is involvement of variety of different specialized innate and adaptive
immune cell types for the coordination of immune response by host cells against harmful
pathogens. The ability of immune cells to execute the given task is the result of their
dynamism and distributed anatomical location. Innate immune cells are mainly myeloid
cells, which include eosinophils, neutrophils, basophils, monocytes, and mast cells
whereas adaptive immune cells are B-lymphocytes and T-lymphocytes which are
specialized to recognize specific antigens (Carmona, Teichmann et al. 2017). Natural
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killer (NK) cells and antigen presenting cells (for example-macrophages and dendritic
cells) link the innate and adaptive immune system (Paul 2011).
Like all other hematopoietic lineages, immune cells are derived from
hematopoietic stem cells (HSCs) in bone marrow (Figure 1.6). HSCs differentiate into

Figure 1.6. Representation of common lineage of immune cells.
Hematopoietic cells differentiate into myeloid and lymphoid
progenitors that further divide into more specific cell types
associated with innate and adaptive immunity respectively
(Torang, Gupta et al. 2019, Grasso and Danani 2020).
multipotent, and lineage committed hematopoietic progenitor cells, such as common
myeloid progenitors (CMP) and common lymphoid progenitors (CLP). These progenitor
cells further divide into more specific cell types of both innate and adaptive immune
system (Fang, Li et al. 2018).
1.5.2. Monocyte derived immune cells
Monocytes are type of phagocytes found in blood stream, bone marrow, and
spleen and do not proliferate in steady state (Auffray, Sieweke et al. 2009). As the
circulating leucocytes, they are crucial for the tissue homeostasis and immunity. Based on
the expression of monocyte surface markers cluster differentiation 14 (CD14) and CD16,
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monocytes can be classical monocytes (high levels of CD14 and no CD16), intermediate
monocytes (high CD14 and some CD16) and non-classical monocytes (low CD14 and
high CD16) (Sprangers, Vries et al. 2016). Despite the several common features, distinct
monocytes have been attributed to specific function. Likewise, classical monocytes
contribute to immunological response during inflammation or injury (Wong, Yeap et al.
2012), intermediate monocytes are involved in antigen presentation, high secretion of
proinflammatory cytokines and parasite recognition (Turner, Bourke et al. 2014)and nonclassical monocytes constantly survey the endothelium (Abderrazak, Syrovets et al. 2015)
Blood monocytes are precursors of the dendritic cells, macrophage, and
osteoblasts which form a heterogenous population of cells with different size and
function. Only classical monocytes are associated with precursor function under
homeostatic conditions whereas the role of intermediate or non-classical monocytes in
steady state remains elusive. There are several recent evidence suggesting the renewal of
tissue macrophages and dendritic cells (DCs) independent of monocytic pool. Rather,
these cells are maintained by longevity and local proliferation during embryonic
development (Hashimoto, Chow et al. 2013).
Under the influence of plasma milieu and signals in tissue, monocytes can
transform into immune cells which are more potent to nullify the adversity due to
invading pathogens (Robinson, Han et al. 2021). In response to the interferon-γ released
by natural killer (NK) cells in inflammation, monocytes are recruited and differentiated
into inflammatory macrophage and DCs (Askenase, Han et al. 2015). Recruitment of
classical monocytes under the of influence of chemokine receptor, CCR2, and its ligands
CCL2, exert and immediate immune response as evidenced by production of high level of
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proinflammatory cytokines like interleukin 1β (IL-1β) and tumor necrosis factor-alpha
(TNF-α) (Jung, Mithal et al. 2015). After the resolution of acute inflammation, classical
monocytes are substituted by intermediate and non-classical monocytes which secrete
anti-inflammatory cytokines and counteract the tissue damage from aggressive immune
response of classical monocytes (Morias, Abels et al. 2015). The fate of differentiated
monocytes after resolving the inflammatory stress is not clear, however, they can
transform into tissue resident macrophage (Yona, Kim et al. 2013). The terminology
defining the distinct population of cells derived from monocytes often differs on the basis
of biological context and, moreover, there could be the overlapping among some of the
population due to lack of consistent markers distinguishing these cells (Orozco, Canny et
al. 2021).
Monocyte derived dendritic cells (DCs) DC are the key regulators in the innate
and adaptive immune system as they are the most common antigen presenting cells. Out
of classical (Collin, McGovern et al. 2013) and plasmacytoid (Laustsen, Van der Sluis et
al. 2021) types of DCs, former is derived from monocytes and later develops in bone
marrow hematopoietic stem cells. Immature DCs can be generated by culturing
monocytes in presence of granulocyte macrophage- colony stimulating factor (GM-CSF)
and they can further differentiate into mature DCs by TNF-α stimulus. Usually,
generation of DCs takes place from pre-DCs, but selected portion of DCs in the dermis
and intestine are regularly replenished by recruitment of classical monocytes (Bain and
Mowat 2014).
Monocyte derived macrophages. Phagocytosis in lymphoid and non-lymphoid
tissues is mainly performed by their resident phagocytic cells, macrophages. They
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maintain the steady state homeostasis by the clearance of apoptotic cells, and production
of growth factors. The expression of broad range of pathogen-recognition receptors
makes them very efficient phagocytic cells and induce proinflammatory cytokines
(Gordon 2002). Macrophages are derived either from the yolk sac or monocytes. Yolksac derived tissue resident macrophages are mainly maintained independently and
mitigate the inflammation and restore homeostasis whereas monocyte derived
macrophages are inflammatory in nature (Mosser, Hamidzadeh et al. 2021). There are
several phenotypically and functionally distinct subsets of macrophages including
microglia of central nervous system, Kupffer cells in the liver, peritoneal macrophages,
splenic macrophages etc (Hashimoto, Chow et al. 2013). Proinflammatory M1
macrophages are differentiated from classical monocytes under inflammatory
environment whereas anti-inflammatory M2 macrophages are originated from the CD16
expressing monocytes after the inflammation get resolved (Sprangers, Vries et al. 2016).
Monocyte derived osteoclasts. Osteoclasts are the special form of macrophages
that are formed by the fusion of monocytes in presence of macrophage-colony
stimulating factor (M-CSF) and receptor activator of NF-қB ligand (RANKL).
Traditionally, osteoclasts are not considered as immune cells but there are some
evidences that show the contribution of these cells to inflammation by antigen
presentation and cytokine release (Meanwell, Fehr et al. 2021).
1.5.3. Microglia as resident macrophage of CNS
The main immune cells in central nervous system (CNS) are microglial cells
which are embryonically derived, self-renewing tissue macrophages involved in shaping
neural circuits during development and throughout life (Ransohoff and Cardona 2010,
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Frost, 2016 #34). They play crucial role in maintaining the brain homeostasis by actively
participating in surveillance of the inter-neuronal space, clearance of dead cells and
debris, and responding to threats (Kettenmann, Hanisch et al. 2011). Microglia
maturation is influenced by transcription factors Irf8 and Sall1, and input from CNS
microenvironment and microbiota. These factors drive the expression of unique genes
encoding surface receptors such as P2ry12, Tmem119 and Trem2, in addition to
macrophage receptors CX3CR1, Mer and Fcgr1. There is subtle difference between the
microglia in different regions as their transcriptional identity is microenvironment
dependent (Song and Colonna 2018). In AD brain, activated microglia surround the
senile plaque (Meyer-Luehmann, Spires-Jones et al. 2008) along with proinflammatory
cytokines ((Dickson, Lee et al. 1993). The accumulation of activated microglia is more
rapid in newly formed plaques (Meyer-Luehmann, Spires-Jones et al. 2008).
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1.6. Toll like receptors (TLRs)
The toll like receptors (TLRs) are one of the tools used by innate immune system
to sense the invasion of pathogenic microorganisms through the recognition of specific
molecular patterns in pathogens. The stimulation of TLRs induces the expression of
specific genes that triggers innate immunity as well as instructs the development of

Figure 1.7. structure of toll
like receptors (TLRs).
antigen specific adaptive immunity. The name “Toll” is taken from a receptor expressed
in insect for the establishment of dorsoventral polarity during development. This protein
is found to be helpful in fighting against fungal infection in insects. There are 11
members of TLRs found in mammals so far which are type-I integral membrane
glycoproteins. Structurally, they are characterized by extracellular ligand binding leucinerich repeat (LRR) motifs and cytoplasmic signal transducing Toll/interleukin-1 receptor
(TIR) domain. Classification of TLRs is based on their ligands, cellular localization, and
position in chromosome. The main distinguishing factor is the molecular patterns in
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pathogens recognized by them. However, the structural basis for ligand specificity is not
understood completely. Some of the TLRs can recognize wide range of molecular
patterns. For example, TLR4 can recognize both exogenous bacterial LPS and
endogenous Aβ.
1.6.1 TLR signaling pathway
Toll like receptor (TLR) signaling pathway is one of the major pathways involved
in the initiation of innate immunity in organisms. The canonical signaling pathway that
lies downstream of Toll/ TLRs is evolutionarily conserved. Stimulation of TLRs by their
corresponding ligands triggers the association of TLRs and the adaptor protein MyD88
(myeloid differentiation primary-response protein 88), which in turn recruits IRAK4 (IL1R-associated kinase 4), thereby allowing the association of IRAK1. The association of
IRAK4 with IRAK1 induces the phosphorylation of IRAK1. Phosphorylation of IRAK1
induces the recruitment of TRAF6 (tumor-necrosis-factor receptor- associated factor 6) to
the receptor complex. After that Phosphorylated IRAK1 and TRAF6 dissociate from the
receptor and form a complex with TAK1 (transforming-growth factor- β-activated kinase,
TAB1 (TAK1-binding protein 1) and TAB2 at the plasma membrane. This event induces
the phosphorylation of TAB2 and TAK1. Phosphorylation of TAB2 and TAK1 degrades
IRAK1 at the plasma membrane, and the remaining complex translocates to the cytosol,
where it binds with the ubiquitin ligases UBC13 (ubiquitin conjugating enzyme 13) and
UEV1A (ubiquitin-conjugating enzyme E2 variant 1). This leads to the ubiquitylation of
TRAF6, which induces the activation of TAK1. Activation of TAK1 leads to the
phosphorylation of both mitogen-activated protein (MAP) kinases and the IKK complex
(inhibitor of nuclear factor-қB (IқB)-kinase complex), which consists of IKK-α, IKK-β
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and IKK-γ (also known as IKK1, IKK2 and nuclear factor-κB (NF-κB) essential
modulator, NEMO, respectively). The phosphorylation of IқB by IKK complex leads to
its ubiquitylation and subsequent degradation. This series of signaling cascade allows
NF-қB to translocate to the nucleus and induce the expression of its target genes.

Figure 1.8. General TLR signaling pathway. After ligand binding, TLRs dimerize
and undergo the conformational change required for the recruitment of downstream
signaling molecules including the, IRAKs, TAK1, TAB1, TAB2 and TRAF6.

1.6.2 TLR4 signaling pathway
Inflammatory response by innate immune system during the infection of gramnegative bacteria is mediated by TLR4 signaling pathway. Lipopolysaccharide (LPS), the
endotoxin present in outer membrane of bacterial pathogens is an excellent ligand for
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TLR4. So, TLR4 signaling pathway initiates with the extraction of LPS from bacterial
membranes by LPS binding protein (LBP) in serum. LPS is then transferred to another
co-receptor, CD14, which can be found either insoluble form or linked to the cell surface
by a glycosyl-phosphatidylinositol (GPI) anchor. LPS from CD14 is then presented to
theTLR4 and MD-2 (TLR4-MD-2) receptor complex. The binding of LPS to the TLR4MD-2 heterodimer dimerizes the complex which brings together their intracellular TIR
domains and creates a scaffold for the recruitment of adaptor proteins (Irvine, El-Agnaf et
al. 2008) and summarized in Figure 1.9. TLR4 then transduces signals via two distinct
pathways, one is MyD88- dependent and another is TRIF-dependent pathways (Figure
1.9). MyD88-dependent pathway proceeds with the recruitment of the adaptor proteins
TIRAP and MyD88 (Kagan and Medzhitov 2006). This triggers a signaling cascade that
comes to an end with the activation of the transcription factor NF-κB and the release of
pro-inflammatory cytokines such as TNFα and IL-6 (Takeuchi and Akira 2010).
Alternatively, TLR4 is internalized into endosomes where it recruits a different set of
adaptor proteins, TRAM and TRIF, which leads to the transcription factor IRF3 and
promote the production of type-I interferons. This pathway is responsible for “late”
activation of NF-κB (Kawai and Akira 2011).The activation of phosphatidylinositol-3OH kinase [PI(3)K], specifically the p110δ isoform, to generate phosphatidylinositol(3,4,5,)- trisphosphate, or PIP3, facilitates the internalization of TLR4 into endosomes
and activation of the TRIF pathway which leads to the dissociation of TIRAP from the
plasma membrane, resulting in its degradation CD14 controls the activation of the TRIF
pathway via TLR4 internalization and production of type-I interferons (Yamada,
Ichikawa et al. 2005) (Zanoni, Ostuni et al. 2011) TRIF pathway is not usual pathway
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that activated upon LPS stimulation, but, in cells which do not express CD14 (Zanoni,
Ostuni et al. 2011), it makes an essential contribution toward the stimulation of an
appropriate immune response.
Out of number of TLRs, TLR4 are the one which best characterized TLRs which

Figure 1.9. TLR4 activation and signaling pathway. TLR4 transduces signals via
two distinct pathways, MyD88 and dependent pathways (Cochet and Peri 2017).
are linked to the signaling and pro-inflammatory response of microglia in many
neurodegenerative diseases including AD. In addition to exogenous LPS ligand, TLR4
can bind with some endogenous components related to many neurodegenerative diseases,
such as, Aβ (Alzheimer’s disease) (Landreth and Reed-Geaghan 2009) and α-synuclein
(Parkinson’s disease) (Choi, Zhang et al. 2020).
1.7. Neuroinflammatory response in AD
Neuroinflammation, mediated in large part by microglia, plays a significant
contributory, and perhaps central, role in exacerbating the neurodegenerative
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environment created by Aβ plaques and neurofibrillary tau tangles in AD (Golde 2022)
(Parhizkar and Holtzman 2022). The association of genes for immune receptors like
TREM2 (Guerreiro, Wojtas et al.) and CD33 (Bradshaw, Chibnik et al. 2013) in AD
strongly implicates neuroinflammation as a key component of AD pathology. Microglia,
the resident phagocytes of central nervous system (CNS) are the main players of this
phenomenon that orchestrate the whole mechanism of inflammation. Continuous
invigilation of assigned brain regions by microglia with their highly motile processes
make them important cellular component for the maintenance of CNS homeostasis (Song,
Jin et al. 2011). Presence of undesired entities such as the protein aggregates or neuronal
death activate the microglia and rush them to lesion. Once the danger associated
molecular patterns (DAMPs) or pathogen associated molecular patterns (PAMPs) get
recognized by germline encoded pattern recognition receptors (PRRs) on microglia, one
of the defense mechanisms in living organisms known as innate immune system, is
initiated to nullify the adverse effects of pathogens (Mogensen 2009). In Alzheimer’s
disease, soluble Aβ or fibrils act as DAMPs or PAMPs to be recognized by microglia via
different PRRs like SCARA1, CD36, CD14, α6β1 integrin, CD47 and Toll like receptors
(TLRs) (Heneka, Carson et al. 2015). So, Aβ deposits/ senile plaques in the brains of AD
patients cause continuous activation of microglia (Gold and El Khoury 2015) with
prolonged release of inflammatory cytokines (Andreasen and Blennow 2002). Results of
in vitro studies from Nichols group (Terrill-Usery, Mohan et al. 2014) and others (Friker,
Scheiblich et al. 2020) (Lučiūnaitė, McManus et al. 2020) confirmed the secretion of IL1β by Aβ-stimulated microglia. An important question is what Aβ species or
conformation is responsible for activating microglia
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1.8. Neurotoxicity in AD
The role of oligomeric Aβ (oAβ) in the progression of AD by the induction of
neuronal damage and cognitive impairment is evidenced by several studies (Kayed and
Lasagna-Reeves 2013). OAβ are the soluble assemble of Aβ monomers formed in the Aβ
aggregation pathway. The higher neurotoxicity of these intermediate Aβ species is a
widely accepted concept. The binding of extracellularly produced OAβ to an array of
receptors on the neuronal membrane surface interferes the homeostatic signaling
pathways of the receptors (Gadad, Britton et al. 2011). Furthermore, the direct interaction
of oligomers and membranes forms pore structure which leads to the change in
membrane integrity and permeability (Mannini, Mulvihill et al. 2014). These are the
interactions which create the toxic environment in brain parenchyma characterized by
Ca2+ homeostasis dysregulation, ROS generation, mitochondrial damage, reduction of
ATP level and abnormal tau phosphorylation. So, there is ultimate dysfunction of the
synapses, neuronal loss, and impairment of long-term potentiation (LTP) due to the
presence of highly neurotoxic soluble Aβ oligomers (Farrugia, Caruana et al. 2020).
1.9. Extracellular vesicles (EVs)
EVs are diverse, membranous phospholipid vesicles released by variety of
mammalian cells. They are the newly defined means of intermolecular communication
other than direct cell-cell contact or transfer of secreted molecules. Most of the bodily
fluids including blood, urine, saliva, breast milk, amniotic fluid, ascites, CSF, bile and
semen circulate EVs. As EVs shuttle variety of biomolecules like proteins,
mRNA/miRNA and DNA they serve as cellular surrogate. on the size and mode of
formation EVs are classified as exosomes and microvesicles. The vesicles formed by the
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outward blebbing of plasma membrane are microvesicles whereas the exosomes are the
result of inward invagination of endosomal membrane pathway. The MVs with the size
of 200-2000 nm, reflect the membrane composition of parent cells and carry the cargo
including nucleic acids and variety of marker proteins. Exosomes are smaller in size ,40200 nm, transport different nucleic acids along with proteins of endosomal sorting
complex required for transport (ESCRT) system and tetraspanin family. The difference in
biogenesis and mechanism of formation between exosomes and MVs implies the
divergent role of these EVs in body. The consensus among various studies for the
accumulation of Aβ peptides in multivesicular bodies (MVBs) before releasing to the
extracellular space implies the importance of EVs in AD research.
1.9.1 Biogenesis of EVs
The knowledge about the mechanism of EV biogenesis and secretion is still in
primitive stage. However, several attempts have been made to address these mechanisms
based on the information for the budding of retroviruses or formation of MVBs
(Colombo, Raposo et al. 2014). The proteomic analysis of EVs from different cell source
suggests the presence of proteins from endosomes, plasma membrane, cytosol and very
few from other intracellular organelles. In general, exosomes are enriched with
endosomal proteins than microvesicles but, the huge overlapping of proteins among
different EV types has reduced the possibility of any universal marker protein for either
class of EVs (Kowal, Tkach et al. 2014). However, tetraspanins, Alix and TSG101 are
considered as marker proteins for exosomes (Shao, Im et al. 2018) and glycoprotein 1b,
external phosphatidylserine and heat shock protein 90B1 (HSP90B1) are some of the
markers for microvesicles. (DeLeo and Ikezu 2018).

27

Exosomes, the smallest extracellular vesicles, are formed as intraluminal vesicles
(ILVs) by inward budding into early endosomes and multivesicular bodies (MVBs). So,
the biogenesis of exosomes starts with the formation of ILVs in endosomal compartments
like MVBs which finally fuse with either endosome or plasma membrane releasing the
exosomal contents (Kowal, Tkach et al. 2014). The most extensively studied mechanism
for the formation of exosomes is the involvement of Endosomal Sorting Complex
Required for Transport (ESCRT) machinery. The four ESCRT complexes (ESCRT-0,
ESCRT-I, ESCRT-II and ESCRT-III) mediate the process of cargo clustering.in

Figure 1.10. Biogenesis of extracellular vesicles. Cellular release of microvesicels
takes place by outward blebbing of plasma membrane whereas exosome pathway
occurs through inward budding of endosomal membrane. Early endosomes formed by
inward invagination of plasma membrane further budded inwardly to form exosomes
as intraluminal vesicles which are secreted by the fusion of multivesicular bodies
with plasma membrane.
ubiquitin-dependent manner, bud formation and vesicle scission. In addition to these
complexes the accessory proteins, especially VPS4 ATPase helps in dissociation and
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recycling of the machinery. Besides the ESCRT machinery, some mechanisms
independent of this are also explained. These mechanisms involve lipids, tetraspanins or
heat shock proteins (Katzmann, Babst et al. 2001, Stuffers, Sem Wegner et al. 2009). The
content of exosomes may include RNA (miRNA, long noncoding RNA and messenger
RNA), mitochondrial DNA, signaling proteins, enzymes, metabolites and lipids. Transfer
of these bioactive molecules from donor cell to distant recipient cells plays vital role in
intercellular communication (Elsherbini and Bieberich 2018).
Microvesicles are formed by the outward blebbing of plasma membrane, which is
the result of redistribution of the phospholipids across the membrane bilayer. The
asymmetry of membrane bilayer maintained by flippase, floppase and scramblase
enzymes is lost during the cell stimulation due to increase in cytosolic Ca2+ (Bevers,
Comfurius et al. 1999).
The activation of p38 cascade after the stimulation of P2X7 by ATP or BzATP via
src-kinase mediated phosphorylation triggers the mobilization of A-SMase of outer
leaflet. Enzyme on the outer leaflet of plasma membrane changes the fluidity of the
membrane there by blebbing and shedding of the MVs. Microvesicles share the topology
of parent cell and characterized by the externalized phosphatidylserine (PS) at their
surface (Zwaal and Schroit 1997, Bianco, Perrotta et al. 2009).
1.9.2 Role of extracellular vesicles in AD
The biogenesis of two main class of extracellular vesicles, exosomes and
microvesicles, suggest different mechanism and contents in them. Because of this
difference, they have entirely different effect in body. But, owing to the size overlap and
centrifugation being gold standard for the isolation of these vesicles, its always one of the
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most challenging parts to distinguish different class of extracellular vesicles. A bunch of
studies are done with the mixed population of extracellular vesicles. Mixed EVs from
CSF and plasma of AD mouse model and medium of PS1 mutant neural cells are
neurotoxic. The neurotoxicity is accompanied by destabilization in Ca2+ homeostasis and
impairment in mitochondrial function. Moreover, Aβ in these vesicles is mostly located
on the outer surface with increased Aβ42/ Aβ40 ratio (Eitan, Hutchison et al. 2016). In a
separate study by Erlandsson group around same time integrates the incomplete
degradation of Aβ in astrocytes and resulting neurotoxicity via secreted microvesicles.
They have noticed astrocytes engulf Aβ-protofibril in mixed co-culture of system of
neurons and glial cells. Thus engulfed Aβ is not degraded by astrocytes rather they
secrete microvesicles loaded with toxic content of astrocytes that contribute to the Aβ
related neurotoxicity (Söllvander, Nikitidou et al. 2016). Injection of mixed EVs from
mesenchymal stem cells (MSC) to the neocortex of APPswe/PS1dE9 AD mice was
effective in reducing the Aβ plaque burden. EVs from MSC-bone marrow cells possess
Neprilysin that facilitates the degradation of Aβ-amyloid (Elia, Tamborini et al. 2019).
Exosomes have been studied to a greater extent than microvesicles (MVs) in the
context of disease pathology. The wide range of bioactive molecules carried by exosomes
make them attractive candidate for biomarker and therapeutic target for many diseases
including neurodegenerative disease like AD. Goetzl et al reported a number of
constituents of Aβ generating system in neuron-derived exosomes (NDEs) and astrocytederived exosomes (ADEs) in AD and frontotemporal dementia (FTDs). Presence of β-site
amyloid precursor protein-cleaving enzyme 1 (BACE-1), γ-secretase, soluble Aβ 42,
soluble amyloid precursor protein (sAPP)β, sAPPα, glial derived neurotrophic factor, P-
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T181-tau and P-S396 has intensified the importance of these vesicles in AD research
(Goetzl, Mustapic et al. 2016). One of the earliest pathological features of AD pathology
is abnormalities in endocytic pathway, which is indicated by the enlargement of MBVs,
accumulation of ESCRT complexes in neurons and Aβ aggregation within late endocytic
compartments of neurons. Willen et al have observed the MBV enlargement under the
influence of Aβ in MVB-dysfunction transgenic mouse model (Willén, Edgar et al.
2017). One of the studies by Hu et al emphasizes the extracellular aggregation of amyloid
beta being enhanced by the amyloid seeds in formed in the endocytic vesicles and
released extracellularly via exosomes. SHSY5Y neuroblastoma cells and cortical neurons
can uptake the extracellular Aβ even at very low physiological concentration and
concentrate in endosomal vesicles. Under normal condition Aβ is cleared up rapidly by
vesicles but continuous exposure to extracellular Aβ overwhelms the degrading capacity
of endosomal/lysosomal pathway and promotes the Aβ-aggregation (Bharadwaj, Dubey
et al. 2009). Bieberich et al have recently reported the Aβ neurotoxicity mediated by Aβ
associated with exosomes. The astrosomes (astrocyte derived exosomes) from transgenic
mouse model of familial AD (5×FAD) or serum of AD patients exhibit significant
neurotoxicity compared to exosomes from wild type or control human serum. The
concentration of Aβ in astrosomes to induce equal neuronal damage is much lower than
without astrosomes. The Aβ associated astrosomes induce caspase activation and
mitochondrial damage once they taken up by neuronal cells. Generation of Aβ associated
exosomes targeting mitochondria by neuronal cells might be one of the novel
mechanisms in Aβ related neurotoxicity in AD (Elsherbini, Kirov et al. 2020). A recent
study by Dimitrios group has implicated the involvement of exosomes in complement-
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mediated neurodegeneration. Astrocytic-origin extracellular (AEVs) from blood of AD
patients can be readily internalized by neurons and induce membrane attack complex
(MAC) on their surface which ultimately leads membrane disruption (Nogueras-Ortiz,
Mahairaki et al. 2020).
Extracellular vesicles are excellent target for various purpose in Alzheimer’s
disease. Application of EVs as biomarker and therapeutics in disease is highly growing
area of research. Ability to carry cargo of several important bioactive molecules from
donor to distant receptor cells has made them critical part of intercellular communication.
The manipulation of Aβ aggregation in extracellular space by the vesicles is the center of
attraction in many ongoing studies around the globe. The detailed and reproducible
studies of this process can open the new avenue in this field.
Despite the lack of excessive research of microvesicles in relation to
neurodegenerative disease, they have also been studied as the transporters of various
biomolecules, mediators of neuron-glia signaling and a secretory pathway for cytokines.
Fruhbeis et al have reviewed several studies demonstrating the role of microvesicles in
intercellular communication in central nervous system (CNS). Microvesicles secreted
from various cells of CNS (astrocyte, microglia and oligodendrocytes) transfer protein
and RNA cargo from one cell to another thereby changing the phenotype of recipient
cells (Frühbeis, Fröhlich et al. 2013). Result that shows the presence of IL-1β in vesicles
shed from ATP stimulated microglia explains the role of MVs in cytokine secretory
pathway. In co-culture study of astrocyte and microglia, the ATP released from astroctyes
activates the P2X7 receptors of nearby microglial cells thereby inducing the release of
microvesicles with cytokines in extracellular space (Bianco, Pravettoni et al. 2005).
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Significant increase in the number myeloid microvesicles in the cerebrospinal fluid (CSF)
of AD patients in comparison to healthy controls strongly suggest the functional
importance of microvesicles in AD pathology (Agosta, Dalla Libera et al. 2014, Joshi,
Turola et al. 2014). A comparatively recent study by spitzer et al. have analyzed the
microvesicular level of CD3, CD4, CD45, CD64, BACE1 Aβ, APP and tau proteins in
CSF of AD patients and healthy controls. They reported reduced concentration of tau and
APP protein in MVs isolated from CSF of AD patients. So, concentration of APP or tau
in microvesicles can be the promising biomarker for the AD. Furthermore, they did not
notice any difference in number and size between the neuronal derived microvesicles for
first time (Spitzer, Mulzer et al. 2019). The study by Verderio group is specifically
significant to emphasize the importance of myeloid derived microvesicles in AD. MVs
derived from the CSF of AD patients convert less toxic aggregates of Aβ42 into highly
neurotoxic soluble Aβ species. Therefore MVs contribute to neuronal death by
manipulating the aggregation of extracellular Aβ (Joshi, Turola et al. 2014). We have
published a result exhibiting the delayed aggregation of Aβ42 monomer in presence of
BV-2 microglial derived MVs. Furthermore, we have also showed the preferred
internalization Aβ42 protofibrils by microglia and its trafficking by shedding the
microvesicles (Gouwens, Ismail et al. 2018).
1.10. Glycomimetic inhibitors of inflammation
The importance of glycobiology has increased following the better understanding
of ability of glycans to encode various biochemical information related to initial stage of
inflammation, infection, or cancer proliferation (Gabius, Siebert et al. 2004). So, a
number of glycosidic or pseudo glycosidic molecules have been investigated for their
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potential use as therapeutic or diagnostic agents (Hudak and Bertozzi 2014). However,
lack of sufficient metabolic stability and permeation properties in addition to their rapid
clearance limit the bioavailability and potency of carbohydrate-based drugs. These issues
can be addressed by the development of chemically modified carbohydrate analogues
called glycomimetics (Ernst and Magnani 2009). So, this class of compounds mimic the
structure of naturally available glycoconjugates and constitute an important therapeutic
lead in several disease treatments (Meanwell, Fehr et al. 2021). It is possible to control
and alter the information directed by glycomimetics so that the sugar encoded
information can be manipulated (Gabius 2018). The objective of glycomimetic design is
to improve the drug like character, chemical and enzymatic stability. Similarly,
glycomimetics are expected to have same or better affinity and selectivity for target
protein in comparison to their corresponding natural counterpart (Tamburrini, Colombo
et al. 2020). Common structural modifications for the design and synthesis of
glycomimetics include the replacement of either endo or exocyclic oxygen atom with
other elements like carbon (Arjona, Gomez et al. 2007), sulfur (Robina, Vogel et al.
2001), (Witczak 1999), phosphorous (Ito, Yamashita et al. 2009) or nitrogen (Compain
and Martin 2007). A broad group of glycomimetics are non-carbohydrate based chemical
entities that mimic the structural and functional features of carbohydrates. For example,
some compounds mimic the acidic nature of sialic acid without any structural
resemblance still interact with carbohydrate binding proteins (Kiefel 2010).
Use of glycomimetics for the intervention of inflammation has greatly widen the
importance of these pharmacologically potent compounds. Inflammation, being the very
common physiological condition in many diseases, is excellent target for the amelioration
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of the adversity created from disease pathology. Owing to their involvement in the
modulation of physiological and pathological processes in cancers, infections,
neurodegeneration and many more, glycosaminoglycan (GAGs) mimetics has been
extensively studied for their potential use in the drug development (Morla 2019). Innate
immune system and corresponding receptors are crucial components of inflammatory
response of cells against various exogenous and endogenous pathogens. (Cao, Cordova et
al. 2021). Toll like receptors (TLRs) constitute an inevitable part of the innate immunity
and have been studied and characterized vigorously. Among the various types of TLRs,
TLR4 are involved in the inflammation induced during gram negative bacterial infection
(Ciesielska, Matyjek et al. 2021). So, an array of TLR4 inhibitors have been validated for
their possible use as anti-inflammatory agents and some of them are under clinical trials.
Glycolipid based TLR4 inhibitors, for example, E-5532, Eritoran, Lipid IVa, etc, are
expecting to have ability to inhibit the bacterial endotoxin induced inflammation (Zhang,
Liang et al. 2022).
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1.10.1

Role of LPS in bacterial infection

Lipopolysaccharide or LPS is a glucosamine-based phospholipid found in the
outer leaflet of the outer membrane of gram-negative bacteria (Sasaki and White 2008).
This remarkable glycolipid is organized into three main structural domains, o-antigen,
core and Lipid A (Figure 1.11) (Trent, Stead et al. 2006). The core sugar consisting of 3deoxy-D-manno-oct-2-ulosonic acid (Kdo) residues, heptoses, and hexoses is attached to
Lipid A composed of 2,3,2’ and 3’ acylated and 1,4’- phosphorylated β (1→6) linked
glucosamine (GlcN) disaccharide in proximal side and to O-antigen made of extended
polysaccharides in distal side (Bertani and Ruiz 2018). However, some bacteria like E.

Figure 1.11. Arrangements lipopolysaccharides (LPS) structural
components. LPS has three chemically, genetically, and biologically
distinct regions, namely-Lipid A, Core and O-antigen.
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coli are viable under suitable conditions even with minimal LPS structure having Kdo2Lipid A only. Despite the structural variations in different components, the overall
structure of LPS is conserved. For example, Lipid A structure undergoes regulated
modifications in response to environmental condition, otherwise it is conserved structure.
Similarly, there is variation in the structure of core oligosaccharides among the species or
even between some strains of one species. O-antigen is the most diverse component of
LPS. The diversity of O-antigen among the bacterial species is so wide that some of the
species do not synthesize this region at all (Klein, Müller-Loennies et al. 2013). In
bacteria LPS executes two major responsibilities. One, it protects gram negative bacteria
in harsh environment so it’s the part of first line defense mechanism. Two, it creates a
barrier against surrounding stress so its indispensable for the viability of bacteria
(Steimle, Autenrieth et al. 2016).
1.10.2

Lipid A based LPS inhibitors

After the discovery that Lipid A (Figure 1.12) is the active component of the LPS
endotoxin in 1957, it created an overwhelming interest in the scientific community and
Shiba and Kusomoto were able to chemically synthesize this biologically valuable
compound in 1985 (Shimoyama and Fukase 2021). A precursor of E. coli Lipid A, lipid
IVa, synthesized by the same group, exhibits the immunostimulant activity in mice but
antagonizes the immunostimulation in human. This finding started the ball rolling for the
investigation of the LPS receptors. These studies the explored various innate immune
receptors including toll like receptors (TLRs). Out of 10 TLRs in humans, TLR4 is the
LPS receptor. TLR4 signaling pathway gets triggered with the recognition of Lipid A by
the receptors and results in the production of proinflammatory cytokines. The complete
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signaling pathway is accompanied by numerous biochemical events and biomolecules.
So, interference of any event or inhibition of any biomolecules can prevent the
production of proinflammatory cytokines.

Figure 1.12. Structure of E. coli lipid A. It consists of a di-glucosamine
backbone,1-and 4’-phosphate groups, and six fatty acyl chains, of which four are
directly linked to the glucosamine head group at positions 2,3,2’ and 3’, and two
are secondary chains attached to the hydroxyl groups of the 2’- and 3’-linked
chains.
One of the strategies for the prevention of bacterial induced inflammation is to
use the small molecules which are either precursor or derivative of Lipid A (Shimoyama
and Fukase 2021). Chemical modification of Lipid A molecules results in the TLR4
active molecules, agonist or antagonist (Federico, Pozzetti et al. 2020). Underacylated
Lipid A variants with less than six acyl chains (e.g., E5564 and OM-174) act as
antagonists by blocking or inhibiting TLR4. Monophophoryl Lipid A (MPLA), a
dephosphorylated derivative of Lipid A and aminoalkylglucosaminide 4-phosphphates
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(AGPs), formed by the replacement of the reducing end sugar with an amino acid, are
common TLR4 agonists being used as vaccine adjuvants and cancer immunotherapeutic
agents. Similarly, Lipid A derivatives with simplified structures like monosaccharides
(GLA and ONO compounds) and mimetics with linear backbone (ER112022) can also
modulate the TLR4 signaling (Lötvall, Hill et al. 2014). Amphiphilic nature of most of
the Lipid A derived TLR4 modulators renders them prone to aggregation in the
concentration range relevant to biological response. In addition to this, amphiphilic
character of these compounds makes them less soluble in water which in turn challenges
their handling in vitro and in vivo. So, the promising future direction could be the
synthesis of compounds with improved water solubility, bioavailability, and reduced
toxicity.
1.10.3

Phosphorous based LPS inhibitors

Phosphorus is the constituent of many biomolecules which are crucial for the life
of organisms. For example, deoxyribonucleic acids (DNA) and ribonucleic acids (RNA)
are polynucleotides containing building units with phosphate group. There are a wide
range of biochemical processes with the involvement of phosphorous containing
compounds. The use of dichlorvos (DDVP) as insecticide and acaricide was banned
because of its acetyl cholinesterase inhibitory properties. Therapeutics for a wide range of
diseases have the formulation with phosphorus containing compounds. Menadiol sodium
biphosphate, developed in 1941 as a vitamin K14 derivative, reduces the risk of
hemorrhage. Based on the functional group with phosphorus, these drugs or prodrugs or
drug candidates can be categorized as phospphoesters, phosphoric amides,phosphonates,
phosphinates, phosphine oxides, phosphoric anhydrides etc. Modifications of existing
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drugs with phosphorus functionalities enhance the selectivity and bioavailability of the
drug by increasing the polarity and strength of hydrogen bonding in vivo (Yu et al.,
2020).
Compounds bearing carbon-phosphorus bond exhibit biochemical,
pharmacological, and toxicological properties. In phosphorus containing glycomimetics,

Figure 1.13. Three classes of phosphorous based glycomimetics.
phosphorus atom replaces anomeric carbon or links to the endocyclic oxygen. The mode
of phosphorus insertion in the ring gives three different classes of compounds, namely
phospha-sugar, phosphino-sugars (phostines), and phosphine-sugar (phostones) (Figure
1.13). Phospha-sugars do not have hydroxyl substituents in ring skeleton so they cannot
be considered as proper carbohydrate analogues. Recently vast number of studies have
been published to indicate the anti-cancer potential of these phosphorus heterocycles
(Kostoudi, 2022). Beside this, sodium phosphate derivatives of many synthetic steroids
including betamethasone, dexamethasone, prednisolone have been developed for the
treatment of inflammation (Kulkarni, Bhattacherjee et al. 1981), (Esselinckx, Bacon et al.
1978), (Benson and Hartley-Asp 1990), (Kostoudi and Pampalakis 2022).
1.10.4

Sugar based anomeric lactones as LPS inhibition

Lactones are cyclic esters of hydroxy carboxylic acids, containing 1oxacycloalkane-2-one structure, or analogues having unsaturation or heteroatoms
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replacing one or more carbon atoms of the ring (Book 2014). Carbohydrate based
lactones constitute the building blocks of many biologically active compounds so

Figure 1.14. A) General structure of lactones. B). Structure of R. sin-1 LPS.

considered as valuable synthon family for the various transformations. This group of
compounds includes aldonolactones, other related monocyclic lactones and bicyclic
systems (Xavier, Rauter et al. 2010). Unusual Lipid A of a nitrogen fixing bacteria,
Rhizobium sin-1, is devoid of phosphate moiety and the glucosamine phosphate is
replaced by 2-aminogluconolactone. Interestingly, Lipid A from R. sin-1 does not
stimulate human monocytes and inhibit E. coli LPS induced TNF-α release (Vandenplas,
Carlson et al. 2002). Test of a wide range of synthetic R. sin-1 Lipid A derivatives have
suggested that the gluconolactone moiety is responsible for antagonizing the LPS induced
cytokine production (Demchenko, Wolfert et al. 2003) (Vasan, Wolfert et al. 2007).
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CHAPTER 2- METHODS
2.1. Aβ42 aliquot lyophilization
Aβ42 was obtained from W.M. Keck Biotechnology Resource Laboratory (Yale
School of Medicine) and prepared following the protocol of Paranjape et al. Briefly,
Aβ42 was dissolved in HFIP, aliquoted, and evaporated. On the following day aliquots
were vacuum-centrifuged and stored in a desiccant at -20˚C.
2.2. Aβ42 monomer, oligomer protofibril and fibril preparation
For the preparation of monomer and oligomer, one aliquot of dry Aβ42 (0.9 mg)
was thoroughly reconstituted in a solution containing 10 mM NH4OH and 6 M
guanidinium hydrochloride (GuHCl) and then incubated for 20-30 minutes at room
temperature. The content was centrifuged for 10 minutes at the speed of 17,000g and the
supernatant was used for isolation of monomeric and oligomeric Aβ42 species using size
exclusion chromatography.
Protofibril preparation was carried out by reconstituting the dry Aβ42 aliquot in
100 µL of 50 mM NaOH followed by 900 µL artificial cerebrospinal fluid (aCSF). After
incubation for 20-30 minutes at room temperature there was as centrifugation step for 10
minutes at 17,000 g. The resulting supernatant was loaded to the Superdex 75 for the
isolation of protofibrils along with monomers.
Fibrils were prepared from aged (generally older than 6 months) monomer
samples. The tubes containing the sample were spun at high speed of 17,000 g for 10
minutes and the resulting pellet were dissolved in required volume of aCSF buffer.
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2.3. SEC isolation of Aβ42
Supernatants of Aβ preparations were fractionated on either a Superdex 75 HR
10/30 column or Superdex 200 HR 10/30 column (GE Healthcare) with a fractionation
range of 3-70 kD using an AKTA FPLC system (GE Healthcare). Both columns have
total volume of 25 mL. Prior to chromatographic isolation of Aβ, bovine serum albumin
(BSA, 5 mg) was passed over the column to limit non-specific binding of Aβ to the
column matrix. Following sample loading, Aβ was eluted at 0.5 mL min−1 in artificial
cerebrospinal fluid (aCSF, 15 mM NaHCO3, 1 mM Na2HPO4, 130 mM NaCl, 3 mM KCl,
pH 7.8) and 0.5 mL fractions were collected and immediately placed on ice. For
Superdex 75, the void volume was 8-9 mL and monomeric Aβ eluted in the included
volume at 16-17 mL. For Superdex 200, the void volume was 8-10 mL and monomeric
Aβ eluted at 17-19 mL. Aβ42 concentrations were determined by in-line UV absorbance
using an extinction coefficient of 1450 cm−1 M−1 at 280 nm for Aβ42.
In order to isolate the more sterile Aβ42 conformations, washing steps mentioned
table-1 were followed to wash the SEC column.
Table 1: Steps of column cleaning
Washing solutions
Change the filter at the top of column
Pen-strep (Same conc as cell culture)
Water
0.1% SDS
Water
NaOH
Water (with 0.1 μg/ml PMX-B)

# column volume (CV)
Not applicable
1
1
1
2
1
1

** aCSF buffer was prepared from sterile water and then sterile filtered. **
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2.4. BV-2 cell culture
BV-2 cells are an immortalized murine microglial cell line derived from primary
murine microglia by stable transfection with the J2 virus, a v-raf/v-myc oncogene
carrying retrovirus (Blasi, et al., 1990). Our BV-2 cells were provided by Dr. Collin
Combs, University of North Dakota, and were maintained in Dulbecco’s modified
Eagle’s medium (DMEM, 4.5 g/L glucose, Hyclone) containing 50 U/mL penicillin, 50
μg/mL streptomycin, 50 μM b-mercaptoethanol, and 5% heat inactivated fetal bovine
serum (FBS, Hyclone) in 75 cm2 flasks (Corning). BV-2 cells were used for their ease of
culture, to isolate microvesicles and to compare the pro-inflammatory activity of distinct
Aβ42 conformations. After thawing, 1 mL BV-2 cells (106 cells/mL) are added to 9 mL
growth medium and centrifuged at 400xg for 10 min. The supernatant is removed by
vacuum aspiration, then the cell pellet is resuspended in 10mL pre-warmed growth
medium, and the cell solution is added to a T75 cell culture flask (Corning). Cells were
passaged once week as follows. Growth medium is removed and, after rinsing with 1 mL
sterile PBS, 1 mL 0.25% trypsin (Sigma) is added to the flask to dislodge adherent cells
from the bottom of the flask. The cells are then incubated for 10 min at 37 °C. 9 mL of
growth medium is added to the flask, and from that volume 3-5 mL (depending on the
density of the under light microscope) are transferred to a 15-mL conical tube, which is
centrifuged at 400xg for 10 mins. In between the passaging there was medium change
step after 2/3 days. For the first passage after thawing, 3-5 mL cells were spun down, and
for the second passage 1 mL was spun down.
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2.5. THP-1 cell culture
THP-1 monocytes purchased from American Type Culture Collection (ATCC,
Manassas, VA) were grown in Roswell Park Memorial Institute (RPMI) 1640 (HyClone,
Logan, UT) containing 2 mM L-glutamine, 25 mM HEPES, 1.5 g/L sodium bicarbonate,
supplemented with 10% FBS (HyClone), 50 U/mL penicillin, 50 µg/mL streptomycin
(HyClone), and 50 µM β-mercapto-ethanol. Cells were maintained at 37°C and 5% CO2
in 75 cm2 (10 mL volume) and 150 cm2 (20 mL volume) Corning culture flasks with
canted necks. The cells were passaged and replenished with fresh growth medium twice a
week. Flasks were changed on alternative weeks.
For cellular assays, THP-1 monocytes were centrifuged and resuspended in a
fresh growth medium containing 10 ng mL-1 phorbol 12-myristate 13-acetate (PMA)
(Sigma) to a cell density of 5×6 105 cells mL-1. Cells were then seeded in a 48-well plate
and differentiated into adherent macrophages for 24 h at 37°C in 5% CO2. The nonadherent cells were removed, and the adherent cells were washed and replenished with
reduced FBS (2%) growth medium with required concentration of treating reagents
(TLR4 antagonists or other proteins).
2.6. PC-12 cell culture
PC-12 cells are derived from a transplantable rat pheochromocytoma, adrenal
gland These cells adhere poorly to plastic and tend to grow in small patches of loosely
attached cells. Cells were obtained from American Type Culture collection (ATCC) and
grown in RPMI 1640 (HyClone, Logan, UT) containing 2 mM L-glutamine and 1.5 g/L
sodium bicarbonate supplemented with 5% FBS, (HyClone) 10% heat-inactivated horse
serum, (Hyclone) and 50 U/ml penicillin/50 g/ml streptomycin Hyclone).
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Frozen cells from liquid nitrogen storage tank were thawed and transferred to
centrifuge tube to spun down at 200 g for 10 minutes at room temperature. The resulting
pellets were resuspended in 10 mL pre-warmed fresh growth medium and transferred to
T75 cell culture flask (Corning). Cell culture flask was maintained at at 37°C in 5% CO2.
Cells were allowed to grow until they become 80% confluent and then they were
passaged in the ratio of 3:7. Cells were passaged once a week and there was medium
change in between the cell passage. Since the cells are loosely adhered to the flask gentle
pipetting of the cells is enough to dislodge the cells from flask.
2.7. Primary microglial cell isolation and cell culture
Primary microglia cells were isolated from wild-type (WT) C57BL/6 mice
(Harlan Laboratories). Microglia were isolated as previously described (Paranjape,
Gouwens et al. 2012) from 3–4 day old mouse pups. Briefly, brains were isolated under
sterile conditions, minced, and trypsinized. The brain tissue was then resuspended in
complete Dulbecco’s modified eagle’s medium (DMEM, HyClone) growth medium
containing 10% fetal bovine serum (FBS), 4 mM L-glutamine, 100 U/mL penicillin, 0.1
mg/mL streptomycin and 0.25 µg/mL amphotericin-B, OPI medium supplement
(oxaloacetate, pyruvate, insulin) (Sigma-Aldrich), and 0.5 ng/mL recombinant mouse
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Life Technologies). The
cell suspension was filtered, centrifuged, resuspended in complete medium and seeded
into Corning 150 cm2 culture flasks with canted neck. Mixed glial cultures were
maintained at 37 °C in 5% CO2 until confluent (1–2 weeks). For experiments, microglia
were detached from the adherent astrocyte layer by shaking the flask at 250 rpm for 6
hours or overnight at 37 °C in 5% CO2 and collecting the medium.
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2.8. Thioflavin-T (ThT) fluorescence measurement
Aβ42 aggregation was probed with binding and fluorescence of ThT which was
assessed as described previously (Nichols, 2002). SEC Aβ fractions were diluted to 4
µmol/L in aCSF pH 7.8 containing 10 µmol/L ThT. Fluorescence emission scans (460520 nm) were acquired on a Cary Eclipse fluorescence spectrophotometer using an
excitation wavelength of 450 nm. Emission scans were integrated from 470-500 nm to
provide a numerical value of ThT relative fluorescence values (RFU)
2.9. Bis-ANS measurement
Bis-ANS (4,4’- Dianinlino-1,1’-binaphthyl-5,5’-disulphonic acid) binding assay
was used to assess the extent of surface exposed hydrophobic residues in distinct Aβ42
conformations isolated from SEC column. Bis ANS fluorescence emission measurements
were done in cuvette (quartz fluorescence cuvette) mode by mixing 10 l of 100 M bis
ANS (stored at 4°C) and calculated volume of Aβ with 80 l aCSF pH 7.8. Emission
scans of 80 l mixture in cuvette were conducted on Cary Eclipse fluorometer using 385
nm excitation and emission scan from 400-600 nm, 10/10 nm slits, 600 V. Emission
scans were integration from 480-600 nm to get the numerical value of bis-ANS relative
fluorescence values (RFU).
2.10. Circular dichroism (CD) measurement
Secondary structure determination of distinct Aβ42 conformations isolated from
SEC column was assessed with circular dichroism (CD) measurement. In this
experiment, samples (minimum 0.2 ml) were placed into a Jasco J0556 quartz rectangular
quartz cuvette with a 0.1 cm pathlength. Spectra were obtained with a Jasco J-1500
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circular dichroism spectrometer by wavelength scan from 260 to 190 nm using a scan
speed of 50 nm/min and an 8 sec data integration time. A response factor of 200
mdeg/1.0 OD was used for all measurements. 20 accumulations of wavelength scans
were averaged for each Aβ sample. Buffer control spectra were averaged and subtracted
from Aβ sample spectra. Each data point ([θ]obs, deg) was converted to mean residue
ellipticity ([θ], deg cm2 dmol-1) with the equation [θ] = [θ]obs × (MRW∕10lc). MRW is the
mean residue molecular weight of Aβ42 (4514.1 g/mol divided by 42 residues), l is the
optical path length (cm), and c is the concentration (g/cm3).
2.11. XTT cell viability assay
This metabolic activity assay was based on the protocol of Scudiero et al. Briefly,
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) and
Phenazine methosulfate (PMS) are diluted to final XTT concentration of 0.33 mg/mL,
and final PMS concentration of 8.34 µM in RPMI without phenol red, supplemented with
2 mM L-glutamine. The assay medium is aspirated from the wells, and 100 µL of test
medium is added. The cells are then incubated at 37˚C in 5% CO2 for two hours. The test
medium is transferred to separate wells of 96 well-plate, and production of the reduced
formazan product is measured via absorbance at 467 nm with a reference wavelength of
650 nm
2.12. PC-12 cell treatment with Aβ42 species
PC-12 neuronal cells were used to compare the neurotoxicity of Aβ42 species.
For the cellular assay, 30,000 cells/200 μl/well in fresh growth medium were seeded to
the 96 well cell-culture plate for overnight at 37°C and 5% CO2. Next day, cell growth
medium was removed, and cells were treated with 5 μM of each Aβ42 species for 24
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hours at 37°C and 5% CO2. All the wells were maintained with equal volume of buffer
(aCSF). Cell treatment with medium only was used as the negative control and 0.5%
triton-X was used as positive control. After 24 hours, conditioned medium was removed
completely and 100 μl of XTT working buffer containing XTT medium (RPMI 1640
medium w/o phenol red or L-gln. Medium is supplemented to 2 mM L-gln) with 0.33
mg/ml XTT (2,3-bis (2-methoxy-4-nitro-5- sulfophenyl)-2H-tetrazolium-5-carboxanilide,
Sigma, X4626 and 8.3 μM PMS (Phenazine methosulfate, Sigma P9625-1G) for 2 hours.
Next, removed the well plate from incubator measured the reduced XTT absorbance at
467 nm with reference wavelength of 650 nm in plate reader.
2.13. Aβ42 treatment of primary microglial cells
Primary microglial cells harvested from glial cell culture were seeded for
overnight and treated with 5 μM Aβ42 protofibril for 45 minutes. Collected the Aβ42 PF
conditioned medium (A1) and washed the cells once with assay medium (A2) and five
times with sterile PBS (W1, W2, W3, W4, and W5) which is followed by treatment with
100 μM BzATP for 30 minutes. Collected the aCSF conditioned with BzATP and washed
the cells with sterile PBS including an acid wash step (W’1, W’2, Acid, W’3, W’4, W’5
and W’6).
2.14. Immuno-dot blot
Cellular uptake of Aβ42 protofibril by primary microglial cells was evaluated by
immune dot-blot assay using protofibril specific antibody, AbSL (affinity purified or
monoclonal). All the washes after Aβ42 and BzATP treatment including cell lysate were
used as samples for the assay. 1.7 μl of each sample were spotted as dots on
nitrocellulose membrane that was soaked in water and dried. The membrane was then
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blocked with blocking buffer (0.1% tween, 5% (w/v) dry milk. Store at 4oC) with
constant shaking of 70 rpm at room temperature for an hour. Blocked membrane probed
with primary antibody (AbSL, 0.036 mg/ml) diluted in antibody diluent (1% milk (w/v),
0.1% tween 20) and incubated at room temperature with constant shaking of 70 rpm for 1
hour. Primary antibody is further probed with Horseradish Peroxidase-conjugated
secondary antibody (anti-rabbit IgG Horseradish Peroxidase-conjugated antibody, R& D
Systems, Cat #HAF008, Lot# FIN1615011, 1:1000 dilution, 2-8oC storage) and incubated
for an hour as earlier. Equal volume of ECL (Enhanced chemiluminescence) substrates A
and B were added and shaken at 120 rpm for 1 minutes. Finally, the membrane was
imaged in dark room using developer and fixer or with gel imager (Bio-Rad, ChemiDoc
MP imaging system)
2.15. MV isolation from the microglial cells
To study the interaction of microglia derived microvesicles and Aβ, microvesicles
were isolated from the primary microglial cells, BV-2 microglial cells and human
microglial cells 3 (HMC3). The isolation method used was basically same with slight
modifications for different cell types.
In the case of BV-2 cells, Confluent cells in T150 flask (Corning) were rinsed
with 5 ml sterile PBS 2x and treated with 4 ml of 1 mM ATP in aCSF for 30 minutes at
37°C and 5% CO2. Conditioned medium was collected and used for MV isolation after
removal of the larger particles by spinning the medium at lower speed of 2.000g for 20
minutes. Supernatant was collected and distributed into four Eppendorf’s tube containing
equal volume and stored at 4°C. The supernatant was centrifuged for 40 minutes at
15,000 g on the same day or next day and the resulted pellets were reconstituted in 500
50

μL buffer. The amount of MVs isolated by this method was not consistent so I started to
use conditioned growth medium from confluent cells to isolate them. This protocol
turned out to be efficient and used for both BV-2 and HMC3 cells.
MVs were isolated only from conditioned growth medium of HMC3 cells. For
this purpose, conditioned growth medium form confluent cells (Usually after a week of
cell passaging) was collected and spun at 2,000 g for 20 minutes to remove the larger
particles like cell debris and apoptotic bodies. The supernatant was collected and divided
into required number of Eppendorf’s tubes, each with 1.5 mL. Thee tubes were then
centrifuged at high speed of 15,000 g for 40 minutes to separate out microvesicle pellets.
All the tubes were randomly divided into two groups and pellet from each group were
reconstituted and combined in 500 μL buffer (acSF or PBS). They further centrifuged at
15,000 g for 40 minutes to get rid of the growth medium and the resulted pellet was
reconstituted in 500 μL buffer. Vesicles were stored at 4°C and used for further studies.
Primary microglial cells harvested by the shaking of glial co-culture flask at 250
rpm for 5 hours at 37°C and 5% CO2 were seeded to the T75 flask for overnight. After
the removal of growth medium, cells were washed 1x with 2 ml sterile PBS and then
treated with 5 μM Aβ42 protofibril diluted in assay medium (growth medium without
FBS) for 45 minutes. Aβ42 conditioned medium was collected, and cells were
extensively washed 4x-5x ad then treated with 2 ml of 100 mM benzoylated ATP
(BzATP) for 30 minutes at37°C and 5% CO2. The BzATP conditioned medium was
collected and the used for MVs isolation using similar method as in BV-2 and HMC3
cells.
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2.16. Size measurement of MVs
First step after the isolation of microvesicles from the different cell types and
method as described in section 2.6, was to determine the size of the particles in MV
samples. Hydrodynamic radius (RH) measurements of microvesicles, were made at room
temperature with a DynaPro Titan instrument (Wyatt Technology, Santa Barbara, CA).
40 μl of samples or syringe filtered buffer were placed directly into a quartz cuvette and
dynamic light scattering intensity was collected at a 90° angle using a 10-s acquisition. In
case of intensity out of instrument size range, either samples were diluted further, or
LASER power was reduced or both dilution and LASER power adjustment were
performed. Auto correlated intensity data were used to calculate particle diffusion
coefficient and converted to RH with the Stokes-Einstein equation. Average RH values
were obtained with Dynamics software (version 6.7.1). Box plots of particle size was
created using data log graph generated by Dynamics.
Nano particle tracking (NTA) analysis was also used to characterize the MVs
from ATP stimulated BV-2 cells. A Malvern LM10 instrument at Southern Illinois
University-Edwardsville (SIU-E) was used to obtain size and concentration data with
assistance from Dr. Timothy McPherson. Briefly, A MV sample (0.5 mL, 100x dilution)
was injected into the LM10 sample holder, and 4-60 s image captures were obtained. The
data were compiled in Nanosight software (v2.3) and values for particle
concentration/mL versus bin center (nm) were provided in the report.
2.17. NBD-C6-HPC measurement
2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino) hexanoyl-1-hexadecanoylsnglycero-3-phosphocholine (NBD C6-HPC) (Life Technologies) is a fluorophore
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conjugate that inserts into phospholipid membranes. The presence of microvesicles in the
isolated in the method 2.6 was probed with NBD C6-HPC fluorescence measurement.
The solution containing MVs was incubated with 20 μM NBD-C6-HPC for 15 minutes at
room temperature and then centrifuged for 40 minutes at 15,000 g. Supernatant was
collected and used as positive control, and resulting pellets were washed three times with
buffer. Finally, pellets were reconstituted in equal volume of buffer as original solution
and washing steps. NBD fluorescence was measured using a Cary Eclipse fluorescence
spectrophotometer. 70-100 μL of the microvesicle-NBD C6-HPC solution was placed in
a quartz cuvette. Emission scans of 500-600 nm were obtained with an excitation
wavelength of 485 nm. The resulting curves were integrated from 520-580 nm to produce
relative fluorescence units (RFU).
2.18. Atomic force microscopy (AFM)
Atomic force microscopy (AFM) was used to observe the surface texture of
microvesicles isolated from different cells. Samples were applied to freshly cleaved mica
that had been modified with 3’-aminopropyl-triethoxysilane (APTES) and incubated for
15 minutes (Nichols et al., 2002, 2005a). The residual sample liquid was aspirated off and
the disk was then rinsed gently with water and blown dry with compressed air. A
Bioscope resolve AFM (Bruker’s Santa Barbara, CA) was used for imaging by ambient
tapping mode. Dr. Bishal Nepal helped to acquire and analyze the images. Images were
obtained in either amplitude mode or height mode, where increasing brightness indicates
greater damping of cantilever oscillation (Harper et al., 1999) or increasing feature
height, respectively. Height mode images were ‘‘flattened’’ prior to measurement of
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particle height distributions with freely available Gwyddion (a modular program for SPM
(scanning probe microscopy) data visualization and analysis) as shown in Figure 2.1.

A

B

C

D

Figure 2.1. AFM images of BV-2 cell derived microvesicles. A) Twodimensional image (height). B) Amplitude. C) Phase. D) Threedimensional image.
2.19. Transmission electron microscopy (TEM)
Transmission electron microscopy (TEM) was used to analyze the annexin V
labeling and probe the Aβ42 protofibrils internalized by the primary microglial cells and
trafficked into microvesicles. LEO-912 Transmission Electron Microscope in Danforth
plant science center and JEOL JEM-2000 FX transmission electron microscope of MIST
lab in UMSL were used to acquire the TEM images. Dr. Philip Fraundorf in UMSL and
Dr. Kirk Czymmek and Dr. Howard R. Berg in Danforth center helped to obtain the TEM
image.
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Samples for TEM were prepared on 300 mesh formvar coated copper grids (Ted
Pella, Inc., prod number 01821, carbon type-A) at room temperature. 10 μl MV samples
in aCSF (1 mM Na2HPO4, 1.5 mM NaHCO3, 3 mM KCl, 130 mM NaCl, pH-7.4) with
appropriate dilution were allowed adsorb on the brighter side of the grid for 10 minutes in
floating mode. Excess sample was blotted with help of filter paper or chem wipes and
grid was washed with TBST (1X PBS with 0.05 % tween 20) buffer or water. Grid was
blocked in blocking buffer (10 % BSA in 1x PBS) for an hour at room temperature. After
the washing step, 5 μL 5x diluted Au-labeled (20 nm) annexin-V was added to the grid
and incubated for 1 hour at room temperature. Washed the grid and stained with 2%
uranyl acetate (Electron Microscopy Services, Hatfield, PA) for 5-10 minutes, removal of
excess solution, and air drying.
A

B

Figure 2.2. TEM images of microvesecles. MVs samples isolated from Aβ42
treated primary microglial cells by BzATP treatment were labeled with A) Auconjugated Annexin-V and B). apAbSL followed by Au-conjugated secondary
Ab and imaged with LEO-912 TEM in Danforth plant science center.
For immunogold labeling, affinity purified AbSL (40-4) was used as primary
antibody and gold conjugated (10 nm) anti rabbit IgG as secondary antibody (G7402, Lot
# SLBZ9393, Pcode: 1002784152). Copper grid with sample were incubated in both
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antibodies for one hour at room temperature. Both antibodies were diluted in blocking
buffer by 100x. Same staining protocol as in annexin-V labeling was used.
TEM was to get high resolution image of Annexin-V labeled MVs along with
Aβ42 protofibrils. But, due to the limitation of primary microglia isolated MVs and
technical expertise in sample preparation desired result was not observed. It was hard to
keep MV intact at room temperature as shown in Figure 2.18.
2.20. Scanning electron microscopy (SEM)
Surface morphology of MVs was further characterized by scanning electron
microscopy (SEM). Dr. Bishal Nepal had helped to acquire and analyzed the SEM
images.
A

B

Figure 2.3. Representative SEM Images of BV-2 cell derived MVs. A) MVs
without any labeling were adsorbed on the Cu-grid and imaged with SEM.
B) Immunogold labeled MVs with Iba1 as primary antibody and Auconjugated antirabbit IgG as secondary antibody.
Samples for imaging were prepared on the 300 mesh copper grids that usually
used to be use for TEM. Minimum amount (10 μl) of MVs were allowed to adsorb on the
brighter side of grid for 10-15 minutes. Excess sample was wicked with chem wipes and
washed with milliQ water 3x. After air drying of grid, SEM images were acquired
without coating of conductive layer. A low voltage between 1 kV to 5kV was applied to
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minimize the charging. Images were captured using ETD Everharth-Thornley detector.
We were able to see particles within the size range of MVs, but SEM was not great
technique to resolve heavy metal labeling in living membranous structure. Some of the
representative SEM images are shown in Figure 2.3.
2.21. Confocal microscopy
Labeling of microglial marker protein, Iba1, and phosphatidyl serine
externalization were assessed with Zeiss LSM (Laser Scanning Microscope) 700 or 900.
Annexin V binding of microvesicles: 200 μl of microvesicle sample in aCSF were
spun at 15,000 g for 40 minutes and the resulted pellets were reconstituted in 200 μl
binding buffer (10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl2, pH- 7.4). 10 μl AF594 labeled annexin V, (Ref- A13203, Invitrogen) was added to the solution and
incubated for 15 minutes. Unbound annexin V was removed by spinning the sample
containing tube at 15,000 g for 40 minutes and labeled vesicles were again reconstituted
in 200 μl binding buffer. 50 μl of labeled MVs was put in a clean glass slide and covered
with coverslips. The samples were imaged under Zeiss LSM 700 confocal microscope
using 561 nm laser as excitation wavelength for fluorophore. Image analysis was done
using ImageJ software (NIH).
Sample preparation for immunofluorescence: immunofluorescence was used to
label Iba1 marker protein in microglial cells (primary microglia, BV-2 microglia and
Hmc3 microglia). 200 μl of (500,000 cells/ml) microglial cells were seeded to poly-dlysine coated Matek-dishes (Part No. P35GC-1.5-14-C, 35 mm petri dish, 14 mm
microwell, No.1.5 cover glass, (0.16 -0.19 mm) for overnight at 37°C and 5% CO2. Cells
were first rinsed with assay medium (growth medium w/o FBS) washed with sterile PBS
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1x and fixed with 0.4% formaldehyde (incubated for 15 minutes at RT). Fixed cells were
washed with wash buffer (0.1% BSA in 1x PBS) 3x and blocked with blocking buffer (10

Figure 2.4. Iba1 is expressed in all microglial cells. Different microglial
cells were labeled with anti-Iba1 and imaged with confocal microscope.
% normal donkey serum, 0.3 %, Triton-x-100 in PBS) for 1 hour at RT with constant
shaking of 70 rpm. Cells were then probed with anti-Iba1 (polyclonal antibody, Catalog
Number PA5-27436, 0.56 mg/ml, Thermofisher Scientific (1:100) for 1 hour and then
with NL493 conjugated IgG secondary antibody (Donkey Antirabbit IgG NL493, Catalog
number: NL 006, (1:200). Finally, cells were counterstained with 0.3 μM DAPI (4’,6diamidino-2-phenylindoledihydrochloride). There was 3x wash steps between each step
and volume used for all reagents was 200. Fixed and labeled cells were stored in 200 μl
PBS at 4°C until imaged with Zeiss LSM confocal microscope systems. Excitation
wavelength of 405 nm was used for DAPI and NL493 fluorophore of secondary antibody
was excited at 488 nm. Images acquired for Iba1 labeling are shown in Figure 2.4.
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2.22. THP-1 macrophage treatment with TLR4 antagonist
Most of the cellular assays for the test of probable TLR4 antagonistic compounds
were carried out in THP-1 macrophages so before the cell treatment calculated volume of
THP-1 monocytes were differentiated as explained in section 2.5.
For cellular treatment, synthetic compounds in solid or liquid form were dissolved
in an appropriate volume of 100 % dimethyl sulfoxide (DMSO) to give a concentrated
working stock solution. AM-12 (1 mg, Kerafast) and its derivatives, and phosphorusbased compounds were brought into 2 mM stock solution whereas sugar lactones were
dissolved to get 20 mM stock solution. The stock solutions were further divided into 20
μL aliquots and stored at -20°C until the biological analysis of compounds. During the
cell treatment stock solution was diluted in DMSO to give the desired concentration
range. The final concentration of DMSO in the cell treatments was always maintained at
0.5% in assay medium.
THP-1 cells for the biological analysis of the compound were obtained from
ATCC (Manassas, VA) and maintained in RPMI-1640 culture medium (HyClone, Logan,
UT) containing 2 mM L-glutamine, 25 mM HEPES, 1.5 g/L sodium bicarbonate, 10%
fetal bovine serum (FBS) (HyClone), 50 units/mL penicillin, 50 μg/mL streptomycin
(HyClone), and 50 μM β-mercaptoethanol at 37°C in 5% CO2. Cellular assay was carried
out in THP-1 macrophages so before the cell treatment THP-1 monocytes were
centrifuged and resuspended in a fresh growth medium to a cell density of 5 x 106
cells/mL. Cells were differentiated into adherent macrophages by treatment with 10
ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma) in 48 well plate for 24 h at 37°C
in 5% CO2. Next day, the growth medium with PMA was replaced with fresh growth
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medium and adherent cells were allowed to grow for another 24 hours in fresh growth
medium. Right before the cell treatment with the compounds, the cells were washed once
with growth medium without FBS (assay medium). Cells were pre-incubated with
different antagonists in assay medium at different concentrations for 30 min followed by
addition of 10 ng/mL ultrapure LPS from E. coli K12 (InvivoGen, San Diego, CA) for 6
h at 37°C in 5% CO2 with 0.5% DMSO used as a control. Following cell incubation, the
conditioned cell medium was collected and stored at -20 °C until analyzed by ELISA for
secreted TNFα production.
In separate experiment where I was testing Am-12 for its activity to antagonize
the Aβ42 protofibril induced TNF-α release, I have used both THP-1 macrophage and
BV-2 microglial cells. The treatment protocol was similar to other treatment protocols,
except for addition of 0.1 ug/ml polymyxin- B (PMX0B) to avoid the cell stimulation by
possible LPS present in Aβ42 sample.
2.23. Sandwich ELISA
TNF-α secreted in conditioned cell medium from THP-1 macrophages treated
with different concentrations of tested compounds was measured by enzyme linked
immunosorbent assay (ELISA) as previously described. (Terrill-Usery, Mohan et al.
2014). Briefly, 96 well plates were coated with 100 μl of 2 μg/ml of monoclonal mouse
IgG1 (MAB-610, R & B) for overnight at room temperature, washed with phosphate
buffered saline (PBS) containing 0.05% Tween-20 and then blocked for 1 hour with PBS
containing 1 % BSA, 5 % Sucrose and 0.05% NaN3. Then 50 μl samples or standards
were added to respective wells in presence of 50 μl sample diluent (20 mM Tris, pH-7.3,
containing 150 mM NaCl,0.1 % BSA and 0.05% Tween-20) and incubated for 2 hours at
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room temperature. This step is followed by addition of 0.1 μg/ml anti-human TNF-α
detection antibody (BAF210, R & D systems) for another 2 hours. Successive steps
involve the incubation of wells with Streptavidin-horseradish peroxide (HRP) conjugate
(20-30 minutes) and equal volumes of HRP substrates 3,3’,5,5’-tetramethylbenzidine and
hydrogen peroxide (20-30 minutes). All these steps were followed by 3x washing steps.
1% H2SO4 solution was used stop the solution. Finally, the optical density of each sample
was analyzed at 450 nm with a reference at 630 nm using a SpectraMax 340 absorbance
plate reader (Molecular devices, Union City, CA). The standard curve for the analysis of
TNF-α in samples was generated by using different concentrations of human TNF-α
recombinant protein (210-RT, R & D systems) ranging from 2000 pg/ml to 15.6 pg/ml in
standard diluent (PBS containing 0.1 % BSA). TNF-α concentrations below 15.6 pg/ml
standard were determined by extrapolation of the standard curve regression line.
2.24. Aβ42 aggregation in presence of exosomes
Aβ42 aggregation assay was carried out to see the effect of SHSY-5Y cells
derived exosomes on the aggregation kinetics of Aβ42 monomers.

Figure 2.5. Schematic of the experimental set up to study the. effect of SHSY-5Y
derived exosomes on Aβ42 monomer aggregation at -4°C.
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SHSY-5Y cell-derived exosomes were shipped from Dr. Elizabeth Eckmann’s
lab, Biomedical Research Institute of New Jersey. They have provided us 3 aliquots
containing 30-35 μl exosomes in each and they have estimated the 0.9 mg/ml total protein
content in the sample. For single experiment, 750 μl solution containing 20 µM Aβ42
monomer (freshly purified using Superdex 200), +/− 30 μl exosomes and aCSF (15 mM
NaHCO3, 1 mM Na2HPO4, 130 mM NaCl, 3 mM KCl, pH 7.4) buffer was prepared in ice

Figure 2.6. Schematic of the experimental set up to study the. effect of
exosomes derived from WT or APP overexpressed SHSY-5Y on Aβ42
monomer aggregation at under different condition.
and divided into 3 siliconized tubes (which provides triplicates for each reaction) after
first reading. The solution tubes were kept at 40C. Measurements were taken at selected
time points by mixing reaction aliquots with thioflavin-T (ThT) and aCSF in fluorescence
cuvette. The final concentration of both Aβ42 monomers and ThT in cuvette was
maintained at 5 μM with total of 100 μl. The extent of aggregation was monitored by ThT
binding and fluorescence measurement. The schematic for this experimental set up is
shown in Figure 2.5.
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Another batch of exosomes derived from wild type (WT) and APP overexpressed
SHSY-5Y cells were received from the same group. This time cells treated with
phosphoramidon (PA) to release the exosomes. Aβ42 aggregation assay was performed to
study the effect of exosomes with and without Aβ42. For a single experiment, 450 μl
reaction mixture of freshly purified Aβ42 monomer with exosomes or PBS in tris buffer
(pH-8) containing 100 μM sodium chloride and 20 μM ThT was prepared in ice. After
first measurement the solution was divided equally into three siliconized tubes. The
aggregation process was optimized for the shaking speed (1000 rpm vs 750 rpm vs no
shaking) and temperature (RT vs 37°C). For each measurement 80 μl reaction mixture
was put in fluorescence cuvette and retained after the measurement. Figure 2.6 shows the
schematic for the experimental set up.
2.25. BCA assay
Protein concentrations in extracellular vesicles or other affinity purified proteins
was measured by a bicinchoninic acid (BCA). BCA assay is based on the reduction of
Cu2+ to Cu1+ by the presence of four amino acid residues (cysteine, cystine, tyrosine, and
tryptophan) and the peptide backbone in protein. Chemically, proteins present in the
sample chelates and reduces the copper in basic solution and the reduced copper further
reacts with BCA resulting in purple color. By measuring absorbance of final solution at
562 nm and comparing the samples to a standard curve generated with bovine serum
albumin, protein concentration in the sample can be determined. A standard curve was
constructed using bovine serum albumin (BSA) diluted in the same buffer as in sample,
typically in the concentration range of 0 μg/mL to 2000 μg/mL. Protein samples (10 μl)
were added to 100 μl of 50:1 mixture of BCA Reagent A to Reagent B (Thermo Fisher
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Scientific) and mixed thoroughly in individual wells of a BCA 96-well plate. The plate
was covered and incubated for 30 min at 37 °C followed by cooling for an additional 10
min. Absorbance was determined for each well at a wavelength of 562 nm using a
SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA).
2.26. AnnexinV-gold conjugation
Gold labeled annexin V required for TEM imaging of microvesicles was prepared
from conjugation of Innova Coat Gold (20 OD) conjugation kit (3 or 10 cryotubes of
Innova Coat Gold, 1 vial of reaction buffer, 1 vial of Ab diluent and 1 vial of quencher)
and purified recombinant Annexin V (Material number 556416,100 ug, 0.5 mg/ml, stored
in buffered solution containing NaN3). First of all, the solutions in conjugate kit were
thawed, and annexin V was diluted in Ab diluent provided with the kit (0.25 mg/ml).
Then, 42 ul of reaction buffer and 12 ul of diluted annexin V were mixed and 45 ul of this
solution is reconstructed in Innova Coat gold and incubated for 15 minutes at room
temperature. The reaction is stopped by adding 5 ul of quencher provided with kit and left
for 5 minutes. To get 100% conjugate free from inbound annexin V, the particles were
washed by adding 10 times of the volume of quencher (diluted in water by 1:10) to the
conjugate solution. The solution was then centrifuged for 40 minutes at 15,000 g and
resulted pellets were reconstituted in diluted (10x) quencher and stored in fridge.
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CHAPTER 3- COMPARISON OF Aβ42 CONFORMATIONS
Accumulation of senile plaques predominantly composed of the amyloid β (Aβ) is
one of the important pathological hallmarks of Alzheimer’s disease (AD) (Bloom 2014).
Aβ is a peptide of 39-42 amino acids generated by the specific proteolytic cleavage of a
transmembrane protein, amyloid precursor protein (APP) in vivo (Chen, Xu et al. 2017).
Self-assembly of Aβ via non-covalent nucleation-dependent polymerization results in
varieties of aggregated structures with variable β-sheet secondary structure (Walsh,
Hartley et al. 1999, Kirkitadze, Condron et al. 2001). Thus, aggregation of Aβ advances
via a number of intermediate structures including oligomers of 3-50 monomers, annular
oligomers protofibrils, fibrils and plaques (Finder and Glockshuber 2007). Not all of
these species are on-pathway to fibril formation (Huang and Liu 2020). The most widely
accepted amyloid cascade hypothesis of AD emphasizes the conversion of Aβ monomers
into an amyloid form as the primary step in the disease pathology (Karran and De
Strooper 2022). Deposition of Aβ fibrils is followed by formation of neurofibrillary
tangles and neuronal death (Hardy and Higgins 1992, Ittner, Chua et al. 2016). A plethora
of studies indicate that soluble Aβ aggregation intermediates possess greater toxicity than
individual monomers or fibrillar plaques (Haass and Selkoe 2007). The mechanisms of
neurotoxicity of aggregated Aβ species include oxidative stress, ion channel formation
and disrupt cell membranes disruption, thereby activating cellular processes such as
apoptosis and inflammation (Carrillo-Mora, Luna et al. 2014).
Generation of Aβ from APP is accompanied by two proteases: β-secretase and γsecretase. APP proteolysis occurs stepwise with the cleavage at the Aβ N-terminus by βsecretase (amyloidogenic pathway) or α-secretase (nonamyloidogenic pathway) to release
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N-terminal fragments APPsβ or APPsα and membrane bound C-terminal fragments C99
or C83, respectively. Both C-terminal fragments undergo further cleavage by γ-secretase
to release extracellular pathogenic Aβ (from C99) or non-pathogenic p3 peptide (from
C83) (Southam, Stennard et al. 2019). Cleavage of C99 by γ-secretase at different sites
yields two major Aβ isoforms, Aβ40 and Aβ42. The presence of two additional Cterminal hydrophobic residues, isoleucine and alanine, renders the latter Aβ42 isoform
more prone to aggregation. Accordingly, increased Aβ42/Aβ40 ratios trigger the onset of
AD (Gu and Guo 2013).
The N-terminal domain of Aβ is derived from the water-soluble extracellular
domain of APP, and the majority of the amino acid residues are hydrophilic. The
transmembrane domain-derived C-terminal segment contains primarily hydrophobic
amino acids giving Aβ an overall amphipathic character (Selkoe 2004). The hydrophobic
middle region (LVFF, residues 17-20) plays an important role in β-sheet formation
(Williams, Portelius et al. 2004). Solid-state NMR (Tycko 2015, Xiao, Ma et al. 2015,
Colvin, Silvers et al. 2016, Walti, Ravotti et al. 2016), and more recently cryo-electron
microscopy (Gremer, Scholzel et al. 2017, Kollmer, Close et al. 2019), studies of Aβ40
and Aβ42 fibrils indicate an underlying structure of two intertwined protofilaments with
hydrogen-bonds running parallel to fibril axis, a well-ordered hydrophobic core, and a
disordered N-terminal region that is not part of the cross-β-sheet structure (Au, Ostrovsky
et al. 2019).
Aβ40 or Aβ42 aggregation yields a complex conformational mixture of species.
NMR structures of Aβ in trifluoroethanol or SDS micelles show the presence of α-helical
conformation with two interconnected helices (Crescenzi, Tomaselli et al. 2002).
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Structural studies of various Aβ aggregation intermediates revealed conformational
switching from α-helix or random coil to β-sheet (Serpell, Sunde et al. 2000). During the
acquisition of β-sheet structure by Aβ on the pathway to fibril formation, the hydrophobic
residues in the middle region of peptide become fully buried in an inner-core nonpolar
environment (Touchette, Williams et al. 2010). The extent of β-sheet structure within
different Aβ intermediates influences solubility, neurotoxicity and neuroinflammation
(Nguyen, Ramamoorthy et al. 2021). The presence of solvent-exposed hydrophobic
residues within oligomeric Aβ intermediates, in conjunction with their size, impacts the
cellular toxicity of these species (Mannini, Mulvihill et al. 2014). Aβ42 protofibrils, with
significant β-sheet structure, stimulate microglia much more robustly than monomers or
fibrils (Paranjape, Gouwens et al. 2012).
The integral role of Aβ aggregation in AD pathology and the key part that soluble
oligomeric intermediates play in the degenerative process is a widely held postulate.
Accordingly, the properties of these pathogenic oligomers that result from misfolding and
aberrant assembly (Bemporad and Chiti 2012) have been scrutinized. The amyloidogenic
E. coli protein HypF-N has been a valuable protein aggregation model (Campioni,
Mossuto et al. 2008, Campioni, Mannini et al. 2010), and it was observed that both
HypF-N oligomer size and hydrophobic exposure impacted neurotoxicity (Mannini,
Mulvihill et al. 2014, Farrugia, Caruana et al. 2020). The concept of exposed
hydrophobic surfaces in oligomeric intermediates was also demonstrated in tau oligomer
preparations compared with tau fibrils (Lasagna-Reeves, Castillo-Carranza et al. 2010).
Neuroinflammation, mediated in large part by microglia, plays a significant
contributory, and perhaps central, role in exacerbating the neurodegenerative
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environment created by Aβ plaques and neurofibrillary tau tangles in AD pathogenesis
(Golde 2022, Parhizkar and Holtzman 2022). The association of genes for immune
receptors like TREM2 (Guerreiro, Wojtas et al. 2013) and CD33 (Bradshaw, Chibnik et
al. 2013) with AD strongly implicates neuroinflammation as a key component of AD
pathology. An important question is what Aβ species or conformation is responsible for
activating microglia. The objective of the current study was to characterize
conformational properties of distinct oligomeric and protofibrillar Aβ species and
evaluate how these properties impact the neuroinflammatory response in microglia
3.1. Isolation of distinct Aβ42 conformational structures
The pathological role of intermediate Aβ species of the aggregation pathway is a
well-established fact in AD. We have observed multiple soluble distinct structural
polymorphs formed during the aggregation of purified Aβ40 F19W monomers. In the
current study we have used Aβ42, which is believed to be the primary trigger of AD.
However, the approach of Aβ42 sample preparation was quite different from the method
used for Aβ40. Commercially available synthetic HFIP treated and vacuum centrifuged
dry Aβ42 were brought into solution using previously described and published methods
from our lab (Nichols, Colvin et al. 2015) (Paranjape, Gouwens et al. 2012) (Gouwens,
Ismail et al. 2018). The dried peptide stored at -20°C was reconstituted in 50 mM NaOH
followed by addition of aCSF (1 mM Na2HPO4, 1.5 mM NaHCO3, 3 mM KCl and 130
mM NaCl, pH 7.8) to get the better yield of protofibril form. After 20-25 minutes
incubation at room temperature, sample was centrifuged at 17,0000 g for 10 minutes. The
resulted supernatant was fractionated in Superdex 75 SEC column. Similarly, for the
isolation of oligomers and monomers, the peptide was reconstituted in a basic 6 M
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guanidine HCl (GuHCl) solution after treatment with 100% HFIP and lyophilization, then
centrifuged at 17,000g for 10 min, and the supernatant eluted on a Superdex 200 SEC
column in aqueous aCSF buffer. The absorbance of eluted solution was determined by inline UV absorbance using an extinction coefficient of 1450 cm-1 M-1 at 280 nm.
The separation chromatogram of Superdex 75 shows two distinct peaks: peak in
void volume for protofibrils at 8-9 ml and peak in included volume at 16-17 ml for
monomers as shown in Figure 3.1 (A.). Unlike the protofibril isolation, there were four
distinct peaks in the separation profile of monomers using Superdex 200. There are two
additional peaks between void peak and monomeric peaks (Figure 3.1 (B)).

Figure 3.1. Isolation of Aβ42 species using size exclusion chromatography (SEC).
Aβ42, prepared and reconstituted as explained in the methods were loaded and
fractionated with (A) Superdex 75 and (B) Superdex 200 column in line with UV
measurement using AKTA FPLC system. Fractions eluted from column were collected
and immediately placed on ice. Shikha Grover helped to isolate Aβ42 several times.
The aggregation kinetics of the Aβ42 is affected by various factors ranging from
their inherent sequence property to physicochemical environment. The aggregation
process is enhanced under basic condition So, reconstitution of dried monomeric form of
Aβ42 in 50 mM NaOH has better yield of protofibrillar form whereas the reconstitution
in mild basic condition (NH4OH) provides much smaller species like monomer and small
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oligomers. The aggregation process advances via several intermediate soluble species so
most of the Aβ preps are characterized with heterogenous mixture of intermediate
species. SEC columns are one of the best tools to separate these various species of
different sizes. The separation range of columns is determined by the size of beads used
in the column. The appearance of extra peaks in Figure 3.1 (B) in comparison to A
illustrates the better separation resolution of Superdex 200 (10,000 Da to 600,000 Da)
than Superdex 75 (3000-70,000).
3.2. Measurement of surface exposed hydrophobic residues
Alzheimer’s disease pathology is directly related to the Aβ misfolding and
subsequent formation of small, neurotoxic oligomers. The understanding of underlying
mechanism of peptide misfolding and resulting oligomerization is of great importance.
There have been hundreds of biophysical studies to unfold this pathogenic mystery. One
of the important parameters change in the process of peptide folding is the extent of
surface exposed hydrophobic residues in the intermediate soluble oligomeric species.
Recently, Mannini et al. observed that smaller oligomer size and greater exposed
hydrophobicity of amyloidogenic N-terminus of the E. coli protein HypF (HypF-N)
(Mannini, Mulvihill et al. 2014) were both directly correlated with neurotoxicity We have
assessed the extent of surface exposed hydrophobic residues using 4,4’-Dianinlino-1,1’binaphthyl-5,5’-disulphonic acid (bis-ANS) measurement. Bis-ANS is a fluorescent
probe for non-polar cavities in proteins. It fluoresces in hydrophobic environments but
negligible fluorescence in water solution. We incubated different Aβ42 species isolated
from SEC column, Superdex 200 and measured the bis-ANS fluorescence emission using
fluorometer.
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The bis-ANS fluorescence of aggregated/protofibrillar Aβ42 eluting in the void
(peak 1 of Figure 3.1 (B)) displayed least bis-ANS fluorescence. Aβ42 oligomer #1 (peak
2 of Figure 3.1 (B)) displayed markedly higher bis-ANS fluorescence, while Aβ42
oligomer #2 (peak 3 of Figure 3.1 (B)) had by far the greatest bis-ANS binding and
fluorescence.

Figure 3.2. Less organized and smaller oligomers have higher extent of surface
exposed hydrophobic residues. Extent of hydrophobic residues in the Aβ 42
species eluted from Superdex 200 was evaluated by bis-ANS fluorescence
measurement as explained in methods. Dr. Nichols helped in data analysis.
There have been numerous reports of conformationally-diverse Aβ species with
different bis-ANS binding. Levine showed that soluble Aβ40 displayed significantly
higher bis-ANS binding, and fluorescence compared to Aβ40 fibrils, and it was proposed
that hydrophobic domains were exposed in a partially α-helical conformation (Levine Iii
2002). Chen et al. followed up on this observation and postulated that bis-ANS binds to
the early aggregation species of aggregation, but the hydrophobic surface is buried in the
higher aggregate assembly (Chen and Glabe 2006). Our observation of higher bis-ANS
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fluorescence of the Aβ42 species eluted lately from the column indicates the possibility
of less organized species in those samples. As the aggregation process advances, there is
increase in the number of much organized structures along with the size increment.
Moreover, this result suggests partially folded structure of oligomers with significant
exposure of hydrophobic domains.
3.3. Measurement of β-sheet structure
Neuroinflammation is another pathological hallmark in Alzheimer’s disease in
addition to Aβ plaques and neurofibrillary tangles (NFT). An inflammatory environment
is created around the senile plaques activating the microglial cells. It has been indicated
that there is a halo of soluble Aβ species which are responsible for activation of
microglial cells and there by releasing the proinflammatory cytokines. Understanding the
structural determinants for proinflammatory stimulation is one of the important aspects of
AD pathology. We have already shown that the protofibrillar form of Aβ42 isolated from
Superdex 75 stimulate both BV-2 and primary microglial cells much more vigorously
than monomers and fibrils (Paranjape, Gouwens et al. 2012). The important structural
difference between non-stimulating monomers and stimulating protofibril is the extent of
ThT binding. It binds to the β-sheet structures and exhibits the increased fluorescence
emission. So, in current study we sought to measure and compare the extent of βstructures in distinct Aβ42 conformations isolated from the Superdex 200 column using
ThT binding and fluorescence measurement assay.
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Figure 3.3. Oligomeric Aβ species are less organized than void
species. Extent of β-sheet structures in different Aβ42 conformation
was probed with the ThT binding and fluorescence measurement as
described in method. Dr. Nichols helped in data analysis.
We observed opposite trend of ThT binding and fluorescence in comparison to
bis-ANS binding. The void fractions that had eluted earlier in isolation process (peak 1 of
Figure 3.1 (B)) exhibit maximum binding with ThT whereas the smaller oligomers had
decreased affinity for for ThT binding.
Thioflavin T (ThT) is the most common dye to monitor the aggregation kinetics
of amyloid proteins. The binding properties and spectral characteristics of ThT were
thoroughly studied by Naiki et al and LeVine ((Naiki, Higuchi et al. 1989), (LeVine III
1993), (LeVine 1995). ThT binding with fibrils causes the drastic change in both
excitation (shifts from 385 nm to 450 nm) and emission maximum changes from (445 nm
to 482 nm) of ThT spectrum and most interestingly, only the fibril bound ThT fluoresce.
The significant enhancement in the ThT fluorescence after binding to ThT is widely
believed to be the result of selective immobilization of a subset of ThT conformers. So,
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our observations of lower ThT binding of oligomers than void/protofibrillar species
implies the lesser extent of β-sheet structures in former conformations.
3.4. Secondary structure measurement of Aβ42
The toxic property of soluble Aβ species is directly related to their secondary
structural arrangements. So, for better understanding of structural elements within the
different Aβ42 populations, particularly oligomers, isolated from Superdex 200, circular
dichroism (CD) was utilized to characterize and compare secondary structure in the SECisolated Aβ42 species. The basis of CD spectroscopy is the different absorptions of right
and left polarized light of asymmetric molecules and considered as one of the fastest
methods to gain first structural information. We have described our typical Aβ42
protofibril preparations in several previous reports (Paranjape, Gouwens et al. 2012,
Paranjape, Terrill et al. 2013, Nichols, Colvin et al. 2015). These previous studies have
shown that Aβ42 protofibrils are a polydisperse population of small soluble curvilinear
structures that bind ThT and have hydrodynamic radii ranging from 10-30 nm.

Figure3.4. Aβ42 oligomers display non-β-sheet secondary structure. Distinct
SEC-isolated Aβ42 species were examined by CD. A) CD spectra were obtained
for Superdex 75-isolated Aβ42 protofibrils (red) and Aβ42 monomers (blue).
Spectra are presented as mean residue ellipticity (θMR). B) CD spectra for
Superdex 200-isolated Aβ42 oligomer #1 (red) and oligomer #2 (blue) were
obtained as in panel A. Dr. Nichols helped to perform experiment and data
analysis.
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SEC-isolated Aβ42 protofibrils (peak 1 Figure 3.1 A) shows a minimum at 218
nm and maximum around 195 nm which is the indication of classical β-sheet structure.
Similarly, monomers (peak 2 of Figure 3.1 A) displayed classical random coil CD spectra
of minimum at 200 nm. (Figure 3.4 A)). However, Superdex 200-isolated intermediate
Aβ42 oligomers had very different CD spectra. Evaluation of Aβ42 oligomer #1 (peak 2
of Figure 3.1 B) spectra revealed a mix of secondary structure elements that were not
fully identifiable (Fig 3.4 B). Aβ42 oligomer #2 (peak 3 of Figure 3.1 B) had a prominent
α-helical spectral signature, two minima at 210 nm and 220 nm (Fig 3.4 B).
3.5. Affinity of AbSL for Aβ42 species
Further characterization of distinct Aβ42 species isolated from Superdex 200 was
carried out using immunoassay. Oligomeric structures along with void species were
probed with monoclonal Aβ42 protofibril-selective antibody (mAbSL113). This antibody
was developed following our earlier characterization of a serum polyclonal AbSL
antibody (Colvin, Rogers et al. 2017). It can distinguish different conformations of Aβ42
as it does not bind with monomers, fibrils or APP. It is very likely that different peptide
species isolated in different peaks of chromatogram have different conformation which
can be distinguished by antibody specific for particular epitopes in the protein structure.
Competition studies of AbSL with other antibody targeting residues 1-16 has indicated
the N-terminal region of protofibrils as the AbSL epitopes (Colvin, Rogers et al. 2017).
Use of conformation specific antibody for the distinction Aβ42 species seems to be the
excellent approach for the objective of our study. Recently, Shikha Grover from our lab
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has expressed monoclonal AbSL (mAbSL) using Freestyle 293-F expression system.
Epitope specificity of monoclonal antibodies way better than polyclonal antibodies.

Figure 3.5. Affinity for Aβ42 intermediate oligomers is less for Aβ42 protofibrilselective AbSL antibody. Distinct Aβ42 species isolated by Superdex 200 were
assessed by indirect ELISA. Aβ42 concentrations for each population were
obtained by UV280 nm absorbance and used to construct the concentration range
of 320 nM-5 nM Aβ42 for plate coating. Absorbance at 450 nm (A450 nm)
represented the final step of the ELISA. Concentration-dependent binding curves
are presented for SEC void peak 1 aggregated/protofibrillar Aβ42 (circles), Aβ42
oligomer #1 (triangles), and Aβ42 oligomer#2 (diamonds) (Experiment
performed by Antanisha Park).
We observed the mAbSL113 antibody clearly favored the
aggregated/protofibrillar Aβ42 species that eluted in Superdex 200 void volume (peak 1
of Figure 3.1 B) (Figure 3.5). The affinity of the antibody dropped considerably for Aβ42
oligomer #1, and even further for Aβ42 oligomer #2 (Figure 3.5) supporting the
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spectroscopic data shown in Figure 3.2, 3.3, and 3.4, demonstrating a less developed, or
different, structure for oligomers.
We did not do the direct bio-physical comparison of void species from the
Superdex 200 and Aβ42 protofibrillar structures isolated using Superdex 75. But
significant affinity of protofibril selective antibody for void species suggests the close
conformational similarity of these species to protofibrils. Again, most likely epitopes for
the AbSL span in N-terminal region of the protofibrils which corresponds to the
extracellular hydrophilic domain of amyloid precursor protein (APP). This means
organization development taking place in the aggregation process is accompanied by the
burying of hydrophobic residues. Presence of surface exposed hydrophobic residues in
oligomers may interfere with the recognition of N-terminal epitopes by AbSL.
3.6. Biological activity of Aβ42 species
As we observed the obvious conformational differences among Superdex-200
Aβ42 species in the spectroscopic measurement and AbSL-based immunoassay, we
sought to see the effect of the oligomers in cellular toxicity. Aβ mediates cellular toxicity
directly by neurotoxicity and indirectly by neuroinflammation. We have previously
observed the robust stimulatory activity of Superdex-75 isolated protofibrils (PF) in both
primary microglial cells and BV-2 microglial cells (Paranjape, Gouwens et al. 2012).
Moreover, PF shows significant ThT binding kinetics which is indicative of β-sheet
structures in them which is similar to the newly Superdex-200 isolated void fractions. So,
we next sought to the compare the neurotoxicity and neuroinflammatory effect of distinct
Aβ42 conformational species on microglial cells. Based on the amounts obtained for each
oligomer population and the limited production/recovery of oligomer #1, cellular studies
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focused on the helical high bis-ANS-binding oligomer #2. Differences in
proinflammatory activity were assessed between Superdex 75-isolated Aβ42 protofibrils
(Figure 3.1 A, peak 1), Superdex 200-isolated Aβ42 oligomer #2 (Figure 3.1 B, peak 3)
and Superdex 200-purified Aβ42 monomers (peak 4). Activity was determined by TNFα
production in BV-2 murine microglia. Similar study was done for the comparison of
neurotoxicity using SHSY-5Y neuronal cells and toxicity was assessed with XTT cell
viability assay.
Superdex 75-isolated Aβ42 protofibrils stimulated nearly 8 times the amount of
microglia-secreted TNFα as that of Superdex 200-isolated Aβ42 oligomer #2 (Fig 3.6 A).
Both oligomer #2 and Superdex 200-purified Aβ42 monomers were similar in
proinflammatory activity with only oligomer #2 statistically higher than buffer-treated
background levels (Figure 3.6 A). In contrary to our expectation, we did not see any
differences in the neurotoxicity of PF and oligomer #2.
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Figure 3.6. Oligomer #2 isolated from Superdex 200 has diminished
proinflammatory but similar non-neurotoxic activity in comparison to
Superdex 75 isolated protofibrils. A) BV-2 microglial cells were treated with
distinct Aβ42 species and the TNF-α secreted by the cells was assessed with
sandwich ELISA as explained in method. B) Neurotoxicity of distinct Aβ42
species was compared in PC-12 neuronal cells. PC-12 cells were treated with
distinct Aβ42 species as explained in method and the cell viability was
assessed by XTT cell viability assay.
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The observation that the proinflammatory response of less developed oligomers
with bis-ANS binding surface exposed hydrophobic residues is significantly diminished
in comparison to β-sheet rich protofibrillar form indicates the role of β-sheet structures in
the disease pathology. Extent of β-sheet structures gradually increases with the
aggregation process and so does the inflammatory effect. But, once the aggregation
process max out to form insoluble fibrillar structure, they are no longer proinflammatory.
One of the reasons for this activity could be the possible interaction of PF with microglial
cells. We have shown the better internalization of PF than monomers (Gouwens, Makoni
et al. 2016). The insoluble nature of fibrils imparts the hinderance in such studies.
Many groups have illustrated the higher neurotoxicity of Aβ species with surface
exposed hydrophobic residues (Mannini, Mulvihill et al. 2014, Capitini, Patel et al.
2018). The hydrophobic nature of both peptide and cell membranes facilitates the toxic
interaction resulting in the neuronal death. However, I did not see differences in the
neurotoxic differences among the distinct Aβ42 species isolated from Superdex 75 or 200
(Figure 3.6 B). This disparity could be real or result of limitation in experimental
approach. I could not test the toxic effect of higher concentration of oligomers due the
limitation of total yield of this conformation in my purification process.
3.7. Conclusion
Understanding the distinct properties between Aβ conformations and how
conformation may impact cellular activity in AD is an open question. There is interest in
the group of soluble oligomeric prefibrillar Aβ species comprising lower molecular
weight oligomers up to larger protofibrils. In my study, a number of strategies were
utilized to separate Aβ protofibrils and oligomers and show that the smaller Aβ oligomers
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have a much different conformation than Aβ protofibrils. Protofibrils bound thioflavin T
to a greater extent than oligomers and were highly enriched in β-sheet secondary
structure. Aβ oligomers possessed a more open structure with significant solvent
exposure of hydrophobic domains as determined by tryptophan fluorescence and bisANS binding, respectively. The protofibril-selective antibody AbSL readily discerned
conformational differences between protofibrils and oligomers. The more developed
structure for Aβ protofibrils ultimately proved critical for provoking the release of tumor
necrosis factor α from microglial cells. The findings demonstrated a dependency on βsheet structure for soluble Aβ aggregates to cause a microglial inflammatory response.
The Aβ aggregation process yields many conformationally-varied species with different
levels of β-structure and exposed hydrophobicity. The conformation elements likely
determine biological activity and pathogenicity. The inflammatory response of microglia
is a key aspect of the pathological brain environment in AD. Thus, knowledge of the Aβ
structural components that allow interaction and stimulation of microglia will help in
identifying therapeutic targets
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CHAPTER 4- INTERACTIONS BETWEEN EVs AND Aβ42
An emerging role of immune cells derived extracellular vesicles (EVs) in innate
immune system has indicated their involvement in the neuroinflammatory diseases
including AD. Based on the biogenesis, size, and cargo, EVs can be of different types as
explained in section 1.9. We have shown that primary microglial cells internalize without
any degradation, one of the highly inflammatory forms of Aβ42, protofibril. The fate of
internalized protofibrils in cellular environment could be helpful to understand the
mechanism of disease pathology, especially, inflammatory environment created in
diseased brain. One of the possibilities is the trafficking of these PFs via the
microvesicles shed by the microglial cells. Microvesicles either spread the pathogenic
Aβ42 form to the healthy region of the brain or help the cell to get rid of these toxic
species. Joshi et al have reviewed this two-edged sword role of vesicles in AD pathology
(Joshi, Benussi et al. 2015). Another important role of immune cell derived extracellular
vesicles could be the effect on Aβ aggregation. My goal in this project was to understand
the mechanism of interaction of extracellular vesicles with Aβ42. The project was based

B
A

Figure 4.1. Schematic of the model for interaction between MVs and Aβ.
A) MVs shed by microglia directly interact with soluble Aβ species
surrounding the senile plaque. B) Aβ species (Especially PF)
surrounding the plaques may be taken up by microglia and trafficked
into MVs. Model designed by Dr. Nichols.
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on the hypothesis that soluble Aβ species surrounding the plaques may be taken up by
microglia and trafficked into MVs (Figure 4.1 A) or interact with microglial-secreted
MVs directly (Figure 4.1 B).
4.1. BV-2 microglial cells derived MVs
By using N9 murine microglial cells and primary mixed culture (containing
astrocytes and microglia) from embryonic rat pups, Bianco and colleagues demonstrates
the microvesicles from microglial cells (Bianco, Pravettoni et al. 2005). Besides, rat
primary microglia (Joshi, Turola et al. 2014) and THP-1 monocytes and HEK (Human
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Figure 4.2. BV-2 microglial cells release microvesicles in extracellular space. A)
Confluent BV-2 cells rinsed with sterile PBS and treated with 1 mM ATP in aCSF for 30
minutes. Conditioned medium was collected and used for MV isolation after removal of
the larger particles by spinning at lower speed of 2.000g for 20 minutes. Supernatant was
centrifuged for 40 minutes at 15,000 g and the resulted pellets were reconstituted in 500
μL buffer. B) Conditioned growth medium from confluent cells was collected and used for
MVs isolation as in panel A.
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embryonic kidney) cells (MacKenzie, Wilson et al. 2001) have also been used to study
the microvesicles. I have used immortalized mucrine microglial cell line BV-2 for MV
isolation. This cell line shares most of the characteristics primary microglial cells (Henn,
Lund et al. 2009). The rapid growth rate and ease in handling and maintaining the cells
made the suitable option for our study. For the purpose of the microvesicle isolation I
grew the cells in bigger flask of 150 cc. Microvesicles were isolated either from the
conditioned growth medium from confluent cells or by ATP treatment of the cells. ATP
is well-known ligand for the stimulation of P2X7 receptors (Wang, Hu et al. 2020).
Differential centrifugation steps were performed to separate out the microvesicles as
shown in Figure 4.2.
Particles isolated from the extracellular medium were characterized by other
biophysical techniques. I was able to isolate the vesicles of the microvesicles size range
with membranous structures. ATP treatment was expected to release higher numbers of
microvesicles, but I was not getting enough yield by this protocol. So, after reviewing
many literatures, I started to use conditioned growth medium for the MV isolation, and it
was helpful to improve the yield. One possible reason could be the time span that growth
medium is exposed to the cells. The cells were treated with ATP for 30 minutes whereas
growth medium was usually exposed for 3 days. So, as the MV release is the continuous
process, there is longer exposure to the cells is likely to accumulate more microvesicles.
Moreover, in ATP treatment I used to use 4 ml treating solution, but cells were growing
in 20 ml of growth medium so using conditioned growth medium provides the isolation
from bigger volume. However, more centrifugation steps were used to completely
remove the component of growth medium.
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4.2. MV isolation from Aβ42 treated primary microglial cells
One of the limitations of BV-2 microglial cells is that they do not internalize
Aβ42 protofibrils. We were aimed to isolate microvesicle containing PF either inside or
on the surface. Primary microglial cells readily internalize highly inflammatory Aβ42
protofibrils. So, I used primary microglial cells isolated from 4-6 days old C57BL/6 mice
pups which were cultured as mixed glia culture and harvested from the culture flask by
constant shaking of 250 rotation per minutes for 6 hours at 37°C and 5% CO2. After
seeding in the cell culture flask, cells were treated first with Aβ42 protofibrils and then
A

B

Figure 4.3. Isolation of microvesicles from Aβ42 protofibril treated primary microglial cells.
A) Primary microglial cells harvested from glial cell culture were treated with Aβ42 as
explained in method section and used to isolate MVs. B.) Dot blot of cell washes and lysate
probed with PF selective AbSL antibody.
with benzoylated ATP (BzATP) for 45 minutes. Cells were washed extensively after Aβ
treatment to remove all the residual Aβ in the flask or on the surface of cells. Finally,
cells were lysed to get cell lysis which was used for further analysis (Figure 4.3 A).
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Conditioned medium after BzATP treatment was used for MV isolation but the
yield was not consistent. I hardly get enough microvesicles to work with. However, some
of the preps had particles within the size range of the microvesicles with membranous
structure. All the cell washes including cell lysate were probed with PF specific ABSL
antibody to evaluate the PF internalization by primary microglial cells. The result (Figure
4.2 B) showed the effective removal of the Aβ42 PF from the cells and presence of
significant amount of PF in cell lysate. This demonstrates the microglial uptake of Aβ42
PF without any conformational change. However, I was not able to probe the Aβ42 PF in
the microglia derived microvesicle.
4.3. Size measurement of microvesicles
The first parameter to characterize the extracellular vesicles is the measurement of
their size. EVs are classified as exosomes and microvesicles and on of the basis for this
classification is the size. Most of the time dynamic light scattering (DLS) was used for
the measurement of size and occasionally we, Dr. Nichols and I, went to SIUE to obtain
nanoparticle tracking analysis (NTA) data. Both of these methods are based on the
Dynamic Light Scattering (DLS)
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Figure 4.4. Size analysis of microglia derived vesicles. A) Dynamic light
scattering was used to get the diffusion coefficients of microvesicle samples
isolated from different cell lines and converted to hydrodynamic radius
(RH). B) Microvesicles derived from BV-2 microglial cells after ATP
treatment were used for NTA measurement in SIUE as described in method.
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diffusion of the particles in solution due to the Brownian motion. But DLS provides only
size range by measuring the diffusion coefficient whereas NTA enables to obtain both
size and density of the particles present in the solution.
Mostly, I was able to see the particles whose sizes were within the size range of
microvesicles (100 nm-1000 nm) in the pellet sample isolated from the different cells.
Figure 4.4 A shows the average sizes of the particles present in the MV preps from
various cells under different condition.
We could not do as many NTA measurements as we wanted to. However, the
result for MV sample isolate from the BV-2 cells after ATP treatment was consistent with
the DLS measurement. It shows the million particles per ml of the solution which was
enough number to analyze the MVs with spectroscopic techniques but not for
microscopic techniques, particularly for confocal microscopy. Here, not only the number
could be the limiting factor but also the extremely size range is not ideal for the
technique. Figure 4.4. B is the representative data from NTA measurement.
4.4. NBD-C6-HPC fluorescence measurement
The lower amount and smaller size of the microvesicle was always a hurdle for
the isolation and analysis. To overcome this issue, use of NBD, a membrane labeling
fluorophore that can be conjugated to various phospholipids to probe the membranous
structures. We used NBD fluorophore conjugated to hexa-phosphatidylcholine (NBD-C6HPC) 9V) which can insert into the lipid bilayers. The insertion of the fluorophore results
in the increased fluorescence with blue shift in the emission spectra.
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Isolated microvesicle suspension was incubated with 20 μM NBD-C6-HPC for 15
minutes and then unbound fluorophore was completely removed with several washing
steps using the buffer (aCSF or PBS).
The fluorescence measurement of the unbound fluorophore, washes and resulted
pellets indicates the presence of membranous particles in the sample (Figure 4.5). In
general, unbound fluorophore has maximum fluorescence which gradually decreases in
washes and bumps up in pellets. Moreover, a significant blue shift in the emission spectra
was observed in all samples. However, the shift was not same for all the sample for some
unknown reason.
This method was not used to quantify the number of vesicles in our sample, but it gives
some qualitative idea on this. Increased fluorescence intensity often related to the number
of fluorophore molecules present in the sample. So, the presented result (Figure 4.5)
shows the best yield for the BV-2 cells and least for primary microglial cells.
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Figure 4.5. NBD-C6-HPC labeling of MVs is helpful to track them. MV samples
isolated from different cells and techniques A) ATP treatment of BV-2 cell, B)
Conditioned BV-2 growth medium C) Aβ42 treated P.microglia growth medium,
D) Aβ42 untreated P.microglia growth medium and E) HMC3 growth medium
were labeled with and measured the fluorescence of NBD-C6-HPC as explained
in method. Number above each bar indicates the wavelength for maximum
emission (λmax).
We labeled the microvesicles with AF594 conjugated annexin V. Annexin V is
known to recognize and bind to the PS. Labeled MVs were observed under confocal
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microscope using excitation wavelength of 561 nm. I was able to see some labeled
micovesicles (Figure 4.5 A) but number of such labeled particles was extremely low. It
might again link to the overall efficiency of MV release and size.
B

A

Figure 4.6. Annexin-V labeling of MVs to probe the phosphatidyl serine (PS)
externalization. A) BV-2 cell derived MVs were labeled with AF-594 cojugated Annexin-V
and observed under confocal microscope after removal of unbound fluorophore. B) MVs
from BV-2 cells were probed with Annexin-V conjugated with gold nanoparticles (20 nm)
in 300 mesh Cu grids and observed under transmission electron microscope after negative
staining with 2% uranyl acetate.

In EM approach, MVs were labeled with annexin V conjugated to gold particles
(Section 2.25) and observed under TEM. TEM images shows the MV labeling with gold
particles which means there were some PS externalized particles but there was not any
definite pattern of shape, instead, they scattered all over the field of view. This indicates
the rupturing of MVs during the sample preparation. I am not able to prepare TEM
sample with intact MVs.
4.5. Effect of exosomes on Aβ42 aggregation
In comparison to microvesicles, the smaller EVs, exosomes are studied much
more extensively. We received SHSY-5Y derived exosomes from Dr. Elizabeth Eckmann
lab in Biomedical research institute, New Jersy. There were two batch of exosomes, first
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batch was derived from SHSY-5Y cells without PA treatment and another batch was
from WT and APP overexpressed SHSY-5Y cells treated with PA. First batch was used
to study the effect on Aβ42 monomer aggregation at 4°C and next batch was used for
similar studies at room temperature or 37°C under quiescent state or under constant
shaking state. The details of the experimental is explained in section 2.24.
Exosomes isolated from WT SHSY-5Y neuronal cells without PA treatment
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Figure 4.7. SHSY-5Y derived exosomes delayed the Aβ42 aggregation.
Exosome samples received from Dr. Elizabeth Eckman’s lab in Biomedical
research institute, New Jersy were assessed for their effect in Aβ42 monomer
aggregation as explained in methods. The experiment was carried out at 4°C for
one month and the Aβ42 aggregation was probed with ThT binding and
fluorescence measurement using Cary Eclipse fluorescence spectrophotometer.
interfere the aggregation process. As illustrated in Figure 4.7, presence of exosomes
slows down the aggregation, lengthening the lag phase. But this experiment was carried
out at low temperature in fridge, so it does not represent the physiological condition. As
the aggregation process is extremely slow at lower temperature, this experiment was
performed for a month.
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So, the next batch of the exosomes were tested at room temperature or 37°C after
some optimization of aggregation condition for more practical experimental time.
However, there was not significant effect of exosomes with or without Aβ42 on the
aggregation process at 37°C with shaking (Figure 4.7 A & B). After this result, I
hypothesized that, shaking of the reaction tubes could avoid the interaction between
B

2500

2500

2000
1500

A
A + exo (WT)
A + exo (APP)

1000
500
0

2000
1500
A
A + exo (WT)
A + exo (APP)

1000
500

2

4

Time (hr.)

6

8

A
A + exo (WT)
A + exo (APP)

4000
3000
2000
1000
0

0
0

C

5000

ThT Fluor (a.u.)

3000

ThT Fluor (a.u.)

ThT Fluor (a.u.)

A
3000

0

2

4

6

Time (hr.)

8

0

5

10

15

20

25

30

Time (hr.)

Figure 4.8. Interaction of Aβ42 monomers and SHSY-5Y exosomes is temperature and
shaking speed dependent. Exosomes derived from WT and APP overexpressing SHSY5Y cells were obtained from Dr. Elizabeth Eckman’s lab in Biomedical research institute,
New Jersy and assessed for their effect on Aβ42 aggregation. The experiments were set at
different. temperature and shaking speed, A) at 37° C and 1000 rpm, B) at 37° C and 500
rpm, and C) at room temperature C and w/o shaking and Aβ42 aggregation was probed
with ThT binding and fluorescence measurement using Cary Eclipse fluorescence
spectrophotometer.
exosomes and monomers. So, we set the experiment at room temperature without
shaking. Under this condition, there was some effect of exosomes to the aggregation
process (Figure 4.7 C) though the effect was very subtle. However, we did not see any
significant distinction between the exosomes with or without amyloid beta on the
aggregation process.
4.6. Conclusion
Extracellular vesicle released by brain cells including glial cells and neuronal
cells play important role in AD pathogenesis. They could be responsible for
dissemination or clearance of pathogenic Aβ species. Microglial cells readily internalize
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the Aβ42 without degradation and I was studying the release of the internalized Aβ42protifibrils via microvesicles released by the outward blebbing of the cell membrane and
their interaction with Aβ42 species. However, lack of excess MVs release by primary
microglia limited my ability to reveal the mechanism of interaction. BV-2 microglial
cells turned out be better model for MV study but their inability of Aβ uptake has limited
the use of BV-2 derived MVs. Characterization of MVs with high resolution microscopic
studies including AFM, TEM and SEM helped to find the way of studying MV surface.
In addition to microglial cell derived MVs, neuronal cell derived exosomes affect the
aggregation of Aβ42 monomers in vitro. But the interaction between exosomes and
monomers is dependent on various parameters like temperature, buffer pH. At lower
temperature exosomes lengthen the aggregation process whereas they could have
opposite effect at high temperature
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CHAPTER 5- IDENTIFICATION OF LPS/TLR4 ANTAGONISTS
From their role as building blocks of nature to their use in pharmaceuticals,
carbohydrates along with their related derivatives have had a profound impact on human
health. Numerous applications of these essential biomolecules exist in many areas of
science and technology. One such application is in inflammatory diseases including
microbial sepsis or many neurodegenerative diseases. Inflammatory response is one of
the mechanisms of innate immune system to overcome the adverse effect of pathogen
during infection and it is mediated my various pattern recognition receptors like TLRs.
TLR4, one of the most studied and best characterized TLRs, mediates the inflammation
in many pathogenic conditions. An outer membrane component of gram-negative
bacteria, lipopolysaccharide (LPS), is the well-known ligand for the TLR4. One
important receptor that senses LPS and triggers the immune response is CD14 which is a
co-receptor in the TLR4 signaling pathway. We, along with other groups around the
globe have implicated the role of same TLR4 signaling pathway in the inflammatory
factor of AD pathogenesis.

Figure 5.1. Structure of AM-12
Significant efforts by many researchers and manufacturers have been made to
develop LPS-based anti-microbial antagonists that target and block the CD14 receptor,
thus terminating the infection/immune response cascade. A large number of synthetic
carbohydrate-based LPS antagonists have been prepared and investigated. Among these,
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LPS antagonist AM-12 (Figure 5.1) developed by Demchenko and Nichols is relatively
simple, stabile, active, and non-toxic. The key structural features of AM-12 include 2,3di-O-alkylated methyl glucoside conjugated to fluorenylmethoxycarbonyl (Fmoc)protected serine via 6-O-succinoyl bridge. The discovery of AM-12 resulted from
evaluation of a medium synthetic library of monosaccharide-amino acid conjugates. AM12 has excellent LPS antagonistic activity without cell toxicity and agonistic activity.
However, IC50 value of 470 nM is relatively higher in comparison to similar disaccharide
analogs.
So, in order to improve the LPS antagonistic activity without cellular stimulation
and toxicity, Dr. Demchenko’s lab synthesized a new series of AM-12 derivatives guided
by docking studies performed in Dr. Maria Kontoyianni at Southern Illinois UniversityEdwardsville (SIU-E). The new series of compounds provided to me are presented in
table 2. At the same time, Dr. Spilling’s lab were synthesizing phosphorus based and
lactone-based sugar to study their ability to antagonize the LPS induced inflammatory
response in immune cells. The main objective in this project was to establish the
structure-activity relationship of these compounds. The peculiarity of these compounds is
their comparatively simpler structures and, ease in the synthetic process. The list of the
compounds is presented in table 2. Only the compounds soluble in 100% DMSO were
studied in for their activity
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Table 2: List of LPS antagonists
AM-12 derivative

Phostones
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Lactone sugars

5.1. AM-12 derivatives
Biological studies of new series of AM-12 derivatives (Table 2) were conducted
to examine and compare their potency of as an antagonist of LPS-induced tumor necrosis
factor α (TNFα) production in human monocyte/macrophage cells. Out of six compounds
provided to us, only three were soluble in 100% DMSO to give the desired concentration.
The solubility of target compound, sulphate derivative of AM-12, GS4p159, was readily
soluble so, antagonistic activity of this target compound alongside its synthetic
intermediates, compounds GS4p147 and GS4p158, have been investigated. THP-1
A.

B.

C.

Figure 5.2. AM-12 derivative compounds have differing degrees of LPS
antagonistic activity. THP-1 macrophages were treated as described in the
Methods with increasing concentrations of compounds GS4p147 (A), GS4p158
(B) and GS4p159 (C), followed by incubation with 10 ng mL-1 LPS (red circles)
or sterile water (green diamonds) for 6 h. Secreted TNFα (pg mL-1) in the
conditioned medium was measured by ELISA. Post-treatment, cell viability was
also assessed (black triangles). The % response for TNFα secretion and cell
viability in each experiment was determined as a percentage of the LPS
treatment with 0.5% DMSO vehicle only (Slater, Dhami et al. 2022).
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monocytes were differentiated to yield macrophages and the cells were treated with LPS
in the absence or presence of the compounds. Compound GS4p158 inhibited LPSstimulated TNFα production in a dose-dependent manner with an IC50 value of 311 nM
(Figure 5.2 (B), circles), which compared favorably with AM-12 (IC50 value of 470 nM).
This compound displayed no cell toxicity (Figure 5.2 (B), triangles) and did not stimulate
TNFα secretion in the absence of LPS (Figure 5.2 (B), diamonds). LPS antagonism by
compound GS4p159 was not as straightforward, as a biphasic effect was observed
(Figure 5.2 (C), red circles). This result suggested more than one binding site. An IC50
value of 13 nM was determined for the possible high affinity site and an IC50 value of ~1
μM was estimated for the low affinity site. Compound GS4p159 was also not toxic to the
macrophage cells, nor displayed any agonist activity (Figure 5.2 (C)). Compound
GS4p147 displayed very little LPS-antagonistic activity and did not stimulate TNFα
secretion alone and was not toxic to cells (Figure 5.2 (A)).
5.2. LPS antagonistic activity of phosphono sugars
In the attempt to obtain the simpler derivatives of Lipid A, Dr. Spilling’s lab
synthesized a series of carbohydrate-based phostones or phosphono-sugars. These
compounds are structurally common in having a phosphorus-oxygen bond in ring hexane
ring but differ in the nature of functional groups present in 1 and 2 position of the ring.
Previous studies of similar compounds had rendered the difficulty in the study of
biological activity due to their compromised solubility. So, they have changed the
functionality of the substituent groups to improve the solubility without harming
stimulating the cells. However, out of four compounds provided to us, one (GG-4 in table
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2) was soluble in in 100 % DMSO. So, I was able to study the LPS antagonistic activity
of rest of the compounds.
From the solubility property of phostones, it can be said that the presence of ether
group bonded to ring phosphorus atom limits the use of the compounds for biological
activity. At the same time compound GG-4 has longest alkyl chain of 15 carbons as one
of the substituents. This could be another factor that made the compound insoluble.
Rest of the compounds, GG-194, GG-197 and GG-196 were readily soluble in
DMSO and implemented for the study of structure-activity relationship of phostones in
inhibition of LPS triggered TNF-α release by THP-1 macrophages. The maximum
solubility of these compounds allowed me to obtain working stock solution of 2 mM. So,
I was able to study the effect 10 μM compound at max under the experimental set up
explained in section 2.22. Further dilution of the compound was carried out using
appropriate volume of 100% DMSO.
The LPS/TLR4 antagonistic activity of the compounds was studied in THP-1
macrophages derived and differentiated from THP-1 monocytes by treating the cell with
10 ng/ml PMA for 24 hours. For the antagonistic and agonistic activity, cells primed with
compounds were further incubated with LPS and sterile water respectively. Relative
viability of the treated cells was evaluated by XTT cell viability assay (section 2.11) and
TNF-α release was assessed with sandwich ELISA (section 2.23).
Antagonistic activity of compound GG-196 coincide with the toxicity result
whereas compounds GG-194 and GG-197 inhibit the TNF-α release without significant
cellular toxicity (Figure 5.2). Only structural difference between toxic and non-toxic
compound is the presence of methyl alcohol group at position 1 of the ring. Most likely,
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presence of alcoholic group in the compounds imparts toxic nature to the compound.
However, substitution of the alcoholic group with ester helps the compound to be nontoxic as well as more soluble.
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Figure 5.3. Phosphono sugars exhibit varying LPS antagonism and cellular
toxicity. Phostones synthesized in Dr. Christopher Spilling were screened for
their LPS antagonistic (red circles) and agonistic (green diamonds) activity,
and toxicity (blue triangles) to THP-1 macrophages after dissolving in 100%
DMSO as explained in methods. The concentration of DMSO was maintained
at 0.5% during the cellular treatments.
One of the consistent results observed with these compounds is the decrease in
activity of the compound with time despite the stock solutions were stored at freezing
temperature of -20°C. So, this result made me think about the stability of compounds in
solution form. Compounds GG-196 and GG-197, which have ester group which are
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known for their lower stability. We were not able to get any solid answer on that as I was
not able to test the status of the compound in solution after long time due to the lack of
appropriate instruments.
5.3. Biological activity lactone sugar
Lactone sugars of various number of carbons (Figure 5.4.1) in the ether group at
2-,3-position were synthesized in Dr. Christopher Spilling’s lab in University of Missouri
St. Louis and I have evaluated these compounds for their anti-inflammatory potential
against LPS-induced TNF-α release in human acute monocytic leukemia (THP-1) cells.
THP-1 cells provide an ideal system for studying inflammatory processes. They serve as
a model for peripheral monocytes/macrophages and their responsiveness to bacterial
infection. We screened a series of lactone sugars with varied chain length at 2- and 3position of lactone ring to identify more biologically relevant lactone sugars of specific
chain length by preincubating THP-1 cells with the compounds prior to cell stimulation
with 10 nM of E. coli LPS as outlined in experimental. Modulation of TNFα production
was analyzed in vitro and measured by ELISA.
THP-1 cells were stimulated with LPS in the presence of increasing
concentrations of compounds to test antagonistic activity. The cells were also treated with
increasing concentrations of compounds in the absence of LPS to examine agonistic
activity. None of the compounds demonstrated agonistic properties. The zero
concentration of compound represents a control treatment of 10 ng/mL LPS and the same
percentage of DMSO included with the compounds.
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LPS antagonistic and cell toxicity properties of compounds were highly
dependent on the length of alkyl chain. Compounds with short alkyl chain, SK_nb3p89
with 3 carbons and SK_nb3p120 with 4 carbons, are not biologically active at all. They
do not exhibit antagonist or agonist or cell toxicity activity. Whereas the antagonistic
activity of SK_nb3p44 (C6) and SK_nb3p119 (C8) overlaps with cell toxicity. So, the
LPS antagonistic activity of lactone sugars with intermediate alkyl chain length may be
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Figure 5.4. Bioactivity of lactone sugars is ether chain length dependent. THP-1
monocyte derived macrophages were subjected to 30 minutes treatment with
compounds in presence of sterile water (blue diamonds) or 10 ng mL-1 LPS (red circles)
for 6 hours at 37°C and 5% CO2. Conditioned medium was analyzed for TNFα secreted
by sandwich ELISA. Adherent macrophages after the collection of conditioned media
were analyzed for cell viability by XTT assay (black triangles).
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attributed to cell toxicity. In contrast, longer alkyl chain is helpful in antagonizing the
LPS induced TNF-α release without significant cell toxicity. However, the extent of
inhibition is dependent on chain length of antagonists. As such, SK_nb3p46 (R= C10H21)
has the optimum alkyl chain length for the concentration dependent inhibition of LPS
signaling without cell toxicity. It can reduce TNF α production up to 11.36% at the
concentration of 100 µM. At the same time when the alkyl chain length has increased to
12 carbons (SK_nb3p61) and 14 carbons (SK_nb3p45), extent of inhibition is 11.55%
and 61.97% respectively at similar concentration of 100 µM.
Table 3: Biological activity of lactone sugar
Compound

Alkyl chain EC50 (μM)

SK_nb3p61

C3H7
C4H9
C6H13
C8H17
C10H21
C12H25

SK_nb3p45

C14H29

SK_nb3p89
SK_nb3p120
SK_nb3p44
SK_nb3p119
SK_nb3p46

Max. inhibition (%)EC50 (Toxicity) Max. toxicity

No inhibition
No inhibition
5.18
2.95
11.4
3.9
0.61

95.75
94.4
88.64
54.45
38.03

No toxicity
No toxicity

No toxicity
No toxicity

5.24
5.58

94.7
86.75
No toxicity
No toxicity
No toxicity

No toxicity
No toxicity
No toxicity

5.4. Conclusion
Use of Lipid A analogs to antagonize TLR4 mediated inflammatory response in
many diseases is a very common strategy. I screened series of compounds that belong to
three different class of compounds, AM-12 derivatives, phosphono sugars and lactone
sugars.
The structure of the new series of AM-12 derivatives was developed based on
predictive computational experiments. LPS antagonism by the target compound,
GS4p159, was not straightforward, and a biphasic effect was observed suggesting a
possibility of more than one binding site. An IC50 value of 13 nM for the new compound
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was determined for the possible high affinity site. Further, the precursor of target
compound, GS4p158 also exhibited improved antagonistic activity over the parent
compound AM-12. Structurally, AM-12 derivatives with better hydrogen bond acceptor
at 4-position of glucopyranoside ring could improve the LPS inhibiting potency
Soluble phostones had excellent LPS antagonizing activity, but the issue of
stability of these compounds in solution form keeps me from making any concrete
decision. However, among the freshly prepared compounds, GG-197, with ester and ether
functional group at position 1 and 2 respectively seems to be strongest inhibitor of LPS.
The biological activity of lactone sugar is mainly determined by the length of
alkyl chains present in 2 and 4 position of lactone ring. Compounds with very short
chain, C3 and C4, do not exhibit any biological activity whereas compounds of
intermediate chain length, C6 and C8 are toxic to the cells. So, a potent compound should
have chain length that can balance the toxicity and antagonistic activity. From the result,
alkyl chain of 10 carbons is optimum for the antagonistic activity.
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5.5. Overall Summary
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Figure 5.5. Interaction of Aβ42 with immune cells. Protofibrillar Aβ42 acrivates TLR4
signaling pathway (A) in immune cells resultimg in the inflammatory response by the cells
(B). In CNS Aβ42 protofibrils are internalized (C) by microglial cells and might be
trafficked (D) into microvesicles released by the cells.
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